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ABSTRACT 
 
 
Neurons are among the most highly polarized cells in the human body. This 
polarization allows the neuron to participate in the transfer of chemical and electrical 
signals which are crucial to the survival of the organism. As part of polarization, each 
neuron develops a dendritic arbor and an axon. To ensure the survival of the cell, 
materials synthesized in the cell body must be trafficked through the axon for delivery 
throughout ultimately ending at the synaptic termini. The bulk of this cargo transport is 
microtubule-based fast axonal transport which is molecular motor mediated and tightly 
regulated though many pathways. Motor based transport is established early in 
development and maintained for the life of the cell. The kinesin motor protein family 
plays an integral role in fast axonal transport and the regulation of these motors is 
essential to proper cargo delivery. Regulation occurs through auto-inhibition, motor 
interactions with microtubule associated proteins (MAPs) and complex signaling 
pathways which control the post-translational modification of MAPs, the microtubule 
track and the motors.  
The disruption of cargo transport is linked to neurodegeneration and disease state 
development. Of particular interest in this process is the MAP Tau which has been 
implicated in a number of neurodegenerative diseases including Alzheimer’s Disease. 
Tau is expressed at all stages of neural development and has been shown to participate in 
signaling cascades, modulate microtubule dynamics and preferentially inhibit kinesin-1 
motility. Though Tau is involved in these processes, the non-disease state regulation of 
this MAP and it’s inhibition of kinesin-1 is not well understood. Tau has been shown to 
bind the microtubule surface in a static-diffusive state equilibrium which differs with 
isoform and lattice. Previous work demonstrates that the static state is more inhibitory to 
kinesin-1 than the diffusive state. These different binding behaviors with their different 
effects on kinesin-1 motility, suggest that cellular regulation of Tau’s static-diffusive 
binding equilibrium may control inhibition of kinesin-1 and that structural changes may 
underlie Tau binding to the microtubule surface. Cellular regulation of Tau’s structure 
and therefore its behavior on the microtubule surface points to a means by which Tau is 
regulated in the non-disease state. Additionally, this would highlight how early changes 
lead to disease state development.  
Using a combination of molecular biology, biochemical techniques and imaging 
strategies including Total Internal Reflection Fluorescence, single molecule Fluorescence 
Resonance Energy Transfer (smFRET) and Alternating Laser Excitation, we show that 
Tau’s static-diffusive state equilibrium is regulated by non-disease state phosphorylation 
at tyrosine 18. Phospho-mimetics are shifted towards diffusive binding and have 
decreased affinity for the microtubule surface which in turn reduces inhibition of kinesin-
1 motility. These results further demonstrate that Tau undergoes long range structural 
change while bound to the microtubule surface. We performed smFRET assays and 
found that Tau binds the microtubule surface in distinct conformations which underlie 
static and diffusive binding. This work ties the regulation of Tau’s structure and binding 
behavior to its function and paves the way for our understanding of how cellular 
regulation acts on multiple levels to fine tune axonal transport.  
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CHAPTER 1: LITERATURE REVIEW 
1.1 Neuronal Development and Degeneration 
1.1.1 The Neuron Theory 
The Nobel Prize in Physiology and Medicine was awarded to Camillo Golgi and 
Santiago Ramón y Cajal in 1906 (Golgi, 1906; Ramón y Cajal, 1906). In his acceptance 
speech, Ramón y Cajal described data generated using staining methods developed by 
Golgi in support of the idea that discrete cellular units called neurons compose the 
nervous system (Ramón y Cajal, 1906).  
During the early years of the development of neurology, work by Ramón y Cajal, 
Van Gehuchten and others revealed that neurons are electrically excitable cells that 
develop a uniquely polarized structure consisting of a cell body from which multiple 
dendrites branch and a single axon extends (Figure 1.1) (Ramón y Cajal, 1906; Pasik et 
al., 1999; Ling et al., 2012; Levitan and Kaczmarek, 2015). The interaction of a dendrite 
with an axon terminal creates a cell-cell junction known as the synapse (Levitan and 
Kaczmarek, 2015). At the synapse, electrical impulses propagated down the axon are 
either directly transmitted to the other neuron or converted to chemical signals which 
bridge the gap between the axon and the dendrite (Levitan and Kaczmarek, 2015).  
2 
Figure 1.1: Pyramidal neuron  
A) The axon of the pyramidal neuron (horizontal arrow) descends to the white matter, 
but also sends branches (vertical arrows) horizontally. Double arrows indicate the 
region shown in the inset, rotated 90° clockwise, that illustrates spiny appendages 
(arrowheads) distributed along a segment of a labeled dendrite. B) Camera lucida 
drawing of the labeled neuron shown in A to illustrate the entire dendritic arbor of the 
neuron. Scale bar: 75 µm in A, 50 µm in B, and 10 µm for the inset in A. Figure and 
legend adapted from Ling et al., (2012) in accordance with the Creative Commons 
Attribution license.  
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1.1.2 Neural Development 
The nervous system begins to develop within the first gestational month (Stiles 
and Jernigan, 2010). In humans on embryonic day 13 (E13), complex signaling pathways 
facilitate gastrulation – the development of three layers of stem cells including the 
neuralectodermal (neural progenitor) cells (Stiles and Jernigan, 2010). These cells will 
eventually give rise to all the components of the brain and central nervous system. Neural 
progenitor cells undergo successive rounds of symmetric cell division between E25 and 
E42 to provide a pool from which neurons can develop (Stiles and Jernigan, 2010). After 
E42 symmetric cell division gives way to asymmetric division which produces one 
progenitor cell and one neuron (Wodarz and Huttner, 2003).  
 
1.1.3 Axonal Development 
Each neuron must develop a dendritic arbor and an axon. Axonal development is 
dependent on growth cone formation (Kalil and Dent, 2014). The growth cone is a mobile 
leading edge which upon development, grows outwards from the cell in response to 
guidance cues such as nerve growth factor (NGF), brain derived neurotrophic factor 
(BDNF), netrins, ephrins and semaphorins (Gibney and Zheng, 2003; Kalil and Dent, 
2014). Netrins ephrins and semaphorins can act as both attractive and repulsive factors 
depending on the receptor present (Moore et al., 2007; Kalil and Dent, 2014). The 
combination of attractive and repulsive cues shapes the trajectory of the growth cone, 
regulates axon branching and prevents axon crossing (Kalil and Dent, 2014). The 
mobility of the growth cone is due to the organization of a complex cytoskeletal structure 
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consisting of both actin and microtubule based components (Kalil and Dent, 2014). The 
growth cone can be divided into a peripheral region of dynamic actin cytoskeleton which 
produces lamellipodia- and filopodia-like structures and a central region with a dense 
microtubule cytoskeleton (Kalil and Dent, 2014). Both actin and microtubules are 
polymers which grow and shrink dynamically (Kalil and Dent, 2014). Actin is a globular 
protein that forms filaments through the binding and hydrolysis of ATP while 
microtubules are comprised of globular tubulin heterodimers that form tubules through 
the binding and hydrolysis of GTP (Korn et al., 1987; Desai and Mitchison, 1997; Kalil 
and Dent, 2014).  
The microtubules in the central region are essential for stabilizing the axon as it 
develops (Kalil and Dent, 2014). These microtubules are organized with their plus ends 
oriented away from the neuronal cell body (Kalil and Dent, 2014). This orientation 
allows the microtubule bundles to act as highways for the retrograde/anterograde 
transport of cargo critical to the development and maintenance of the axon (Kalil and 
Dent, 2014). Cargo transport is largely a molecular motor based process which is tightly 
regulated by the cell (Stenoien and Brady, 1999) . 
 Neurons establish polarity once they exit the cell cycle (Barnes and Polleux, 
2009). In some cases, polarity is the result of the apico-basal arrangement of the cell as is 
the case for mouse retinal ganglion cells (Figure 1.2) (Barnes and Polleux, 2009). Upon 
cell cycle exit, the cell body migrates from the apical to the basal membrane forming a 
trailing and leading process (Polleux and Snider, 2010). Dendrites develop from the 
apical process while the axon is formed from the basal process (Figure 1.2) (Barnes and 
Polleux, 2009). Not all neuronal cell types immediately form a single trailing and leading 
5 
edge. Mouse pyramidal neurons for example, through the action of cyclin dependent 
kinase 5 (Cdk5), produce many processes or neurites before a trailing (axon) and leading 
(dendrites) process form (Figure 1.3) (Barnes and Polleux, 2009; Liu et al., 2016). 
Polarization is therefore the result of cross-talk between extracellular cues, intracellular 
signaling and extensive cytoskeletal rearrangements.  
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Figure 1.2: In vivo polarization of retinal ganglion cells in zebrafish (Danio rerio) 
and mouse (Mus musculus). 
Neuroepithelial progenitors characterized by an apical and a basal attachment undergo 
asymmetrical cell division at the apical surface (1–3). Upon cell cycle exit, the nucleus 
undergoes basal translocation (4) and specifically loses its apical attachment while its 
basal process starts growing along the basal membrane (5). The axon (purple) develops 
from the basal process and the dendrite from the apical process (6; green). Figure and 
legend adapted from Barnes and Polleux, (2009). Republished with permission of Annual 
Review of Neuroscience from Barnes, A.P., and Polleux F. (2009). Establishment of 
axon-dendrite polarity in developing neurons. 32, 347-381 permission conveyed through 
Copyright Clearance Center, Inc. 
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Figure 1.3: Polarization of radially migrating pyramidal neurons in the mammalian 
neocortex. 
Neurons are generated between E11 and E17 by radial glial progenitors in the ventricular 
zone (VZ) of the mouse neocortex. These cells have a long basal process attached to the 
basal membrane and a short apical process on the ventricle side (1). Upon cell cycle exit 
through asymmetric cell division (2), the postmitotic neuron (blue) goes through a 
multipolar transition where multiple neurites emerge rapidly from the cell body (3) before 
two major processes form (4) and become the leading process (LP) and trailing process 
(TP). The cell body continues to translocate toward its final destination while the axon 
rapidly elongates (6). The leading process gives rise to the apical dendrite (green in 7), 
which initiates local branching in the marginal zone (MZ) while over the first postnatal 
week (until radial migration ends) the cell body will translocate ventrally (8). Figure and 
legend adapted from Barnes and Polleux, (2009). Republished with permission of Annual 
Review of Neuroscience from Barnes, A.P., and Polleux F. (2009). Establishment of 
axon-dendrite polarity in developing neurons. 32, 347-381 permission conveyed through 
Copyright Clearance Center, Inc. 
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 In mammals, axons have been shown to develop in response to external growth 
cues such as BDNF (Polleux and Snider, 2010). In in vitro experiments with hippocampal 
neurons plated on stripes of adhesion molecules, the neurite which encounters BDNF first 
becomes the axon (Shelly et al., 2007). BDNF acts through Ras mediated activation of 
cyclic adenosine monophosphate (cAMP) dependent protein kinase (PKA) (Figure 1.4) 
(Shelly et al., 2007). Repulsive cues such as semaphorin 3A play a role in directing axon 
development in cortical neurons where axons develop ventrally (Polleux et al., 1998; 
Chen et al., 2008). In Caenorhabditis elegans, axonal development is regulated by netrin 
and its receptors deleted in colorectal cancer (DCC) and Uncoordinated 5 (unc-5) (Adler 
et al., 2006). Soluble netrin gradients act as attractive cues in the presence of DCC (Adler 
et al., 2006). With repulsive cues directing growth away from an undesirable area and 
gradients of attractive cues promoting growth in another direction, the growth cone can 
be steered to its final destination. Downstream effectors of netrin/DCC signaling include 
phosphatidylinositol 3 kinase (PI3K), phosphatase and tensin homolog deleted on 
chromosome 10 (PTEN) and the Ena/VASP (enabled/Vasodilator-
stimulated phosphoprotein) homolog unc-34 which binds actin promoting filament 
formation and therefore filopodia formation (Fleming et al., 2010; Polleux and Snider, 
2010).  
 In response to external cues (such as BDNF or netrin), the serine/threonine 
kinase, liver kinase B1 (LKB1; in C. elegans Par-3) is translocated from the nucleus upon 
dimerization with sterile20-related kinase adaptor (STRAD) α/β (Dorfman and Macara, 
2008) (Figure 1.4). In the cytoplasm, LKB1/STRAD is activated by PKA 
9 
phosphorylation (Collins et al., 2000). LKB1/STRAD in turn propagates this signal by 
phosphorylating and activating the microtubule affinity regulating kinases (MARK) 1-4 
which regulate microtubule dynamics by phosphorylating microtubule associated proteins 
(Figure 1.4) (Polleux and Snider, 2010).  
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Figure 1.4: Signaling pathways governing axonal development.  
External signaling cues such as netrins and BNDF, once bound to their receptors, activate 
signaling pathways that ultimately converge on the cytoskeleton. Gradients of these 
signaling cues direct axonal growth during development. Figure and legend created based 
on Barnes and Polleux, (2009) and Polleux and Snider, (2010). 
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 Ras activation also leads to PI3K activity (Polleux and Snider, 2010; Zhong, 
2016). PI3K has been shown to accumulate in the neurite destined to become the axon 
(Barnes and Polleux, 2009). Constitutively active PI3K overexpression leads to the 
development of multiple axonal processes while inhibition prevents axon formation 
(Barnes and Polleux, 2009). PI3K activity is antagonized by PTEN (Barnes and Polleux, 
2009). PTEN dephosphorylation of phosphatidylinositol triphosphate (PIP3), the product 
of PI3K activation, limits PI3K signaling (Barnes and Polleux, 2009). Spatial regulation 
of PI3K signaling by PTEN allows for single axon development (Barnes and Polleux, 
2009). Overexpression of PTEN leads to the loss of axonal development while PTEN 
knockdown allows multiple axons to develop (Barnes and Polleux, 2009).  
 PI3K downstream effectors include protein kinase B (AKT) which is recruited 
to the membrane via PIP3 binding to its plextrin homology domain (Zhong, 2016). Once 
at the membrane, AKT is phosphorylated and activated by other membrane targeted 
kinases (Barnes and Polleux, 2009). Active AKT has been shown to localize to polarized 
growth cones and constitutively active AKT gives rise to multi-axon neurons (Barnes and 
Polleux, 2009). This mimics the effect of PI3K overexpression and places AKT in the 
PI3K pathway governing polarization.  
Given the dynamicity of the growth cone, it is not surprising that the signaling 
cascades dictating axonal development converge on the cytoskeleton. In some instances, 
the action of the cytoskeleton controls signaling forming a type of feedback loop. PI3K 
for example, interacts with Shootin1 (Toriyama et al., 2006) and Singar 1/2 (Mori et al., 
2007). Of these two proteins, Shootin1 overexpression is sufficient to cause multi-axon 
12 
development (Barnes and Polleux, 2009). Interestingly, Shootin1 is transported to the 
growth cone in a myosin dependent manner where is co-localizes with active PI3K 
(Barnes and Polleux, 2009). Additionally, evidence suggests there are two pools of PIP3 
at the growth cone, one produced by locally active PI3K and another transported pool 
(Barnes and Polleux, 2009). The transportation of PIP3 vesicles to the forming axon is 
dependent on guanylate kinase associated kinesin (GAKIN) (Barnes and Polleux, 2009). 
GAKIN mediated transport of extra PIP3 may help maintain axon integrity through 
maintenance of a high PIP3 concentration.  
 At the heart of polarity regulation lies glycogen synthase kinase 3 β (GSK3β). 
GSK3β is constitutively active in its unphosphorylated form (Barnes and Polleux, 2009; 
Polleux and Snider, 2010). GSK3β sits at the crossroads between signal cascades and 
direct regulation of cytoskeletal elements. GSK3β is phosphorylated and deactivated by 
AKT in the forming axon (Barnes and Polleux, 2009). Global inhibition of GSK3β 
activity leads to multi-axon formation indicating that GSK3β activation must be 
maintained in neurites destined to become dendrites while GSK3β must be inhibited by 
AKT during axonal development (Barnes and Polleux, 2009).  
The cytoskeleton then must support the transport of factors needed for axonal 
development while rapid rearrangement occurs. This rearrangement occurs through the 
action of multiple regulating proteins in addition to Ena/VASP such as collapsing 
response mediator protein-2 (CRMP-2) (Barnes and Polleux, 2009). CRMP-2 is regulated 
by GSK3β and binds directly to tubulin and the WASP-family verprolin homologous 
(WAVE) protein complex to regulate both microtubule and actin dynamics (Barnes and 
Polleux, 2009). Adenomatous polyposis coli another microtubule binding protein 
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regulated by GSK3β, is enriched in the forming axon at early time points (Barnes and 
Polleux, 2009). GSK3β has also been shown to alter the phosphorylation state and 
behavior of the microtubule associated proteins (MAPs) Tau and MAP1b (Barnes and 
Polleux, 2009).  
 
1.1.4 Neurodegeneration 
 The pathways that govern neural development and maintain cell function are 
susceptible to myriad insults which eventually lead to disease state development. These 
insults include environmental factors, traumatic injury, inherited and spontaneous 
mutations, and disrupted/misregulated signaling (Brady and Morfini, 2017; Prior et al., 
2017; Wilson et al., 2017). Whether the insult is intra- or extracellular, the end result is 
synapse loss and the eventual death of the neuron (Liu et al., 2011; Brady and Morfini, 
2017; Prior et al., 2017).  
One of the hallmarks of disease state development and neurodegeneration is the 
disruption of cargo transport through the axon (Brady and Morfini, 2017; Prior et al., 
2017). The molecular motor mediated movement of cargo is established during 
development and is maintained throughout the life of the cell (Brady and Morfini, 2017). 
In the disease state aberrant signaling by misregulated kinases leads to inhibition of 
motors and regulatory elements (Kanaan et al., 2013; Martin et al., 2013b).  
Though many kinases contribute to disease state development (Martin et al., 
2013b; Brady and Morfini, 2017), for the sake of brevity only the action of GSK3β and 
Cdk5 will be covered. GSK3β activity is regulated through inhibitory phosphorylation at 
serine 9 (Kirouac et al., 2017). The tight control of this site allows for normal axonal 
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development and neuronal signaling (Llorens-Martin et al., 2014; Kirouac et al., 2017). 
Disruption of signaling pathways (such as AKT activity) that inhibit GSK3β are common 
to the development of neurodegenerative disease (Llorens-Martin et al., 2014).  
In the development of Alzheimer’s Disease (AD), aberrant signaling through 
amyloid precursor protein (APP) has been shown to upregulate GSK3β activity (Kirouac 
et al., 2017). Disease state processing of APP by β- and γ-secretase generates the 
extracellular fragment amyloid β (Aβ) and the APP intracellular fragment (AICD) 
(Kirouac et al., 2017). AICD has been shown to bind and upregulate GSK3β which in 
turn phosphorylates APP at threonine 688 increasing disease state cleavage (Kirouac et 
al., 2017). This creates a positive feedback loop which keeps GSK3β active in the disease 
state. As part of its non-disease state roles, GSK3β regulates cytoskeletal elements 
(Barnes and Polleux, 2009; Polleux and Snider, 2010). Increased GSK3β activity leads to 
increased phosphorylation and misregulation of these elements including molecular 
motors such as kinesin-1 and MAPs such as Tau (Llorens-Martin et al., 2014; Brady and 
Morfini, 2017). GSK3β is also upregulated independently of AICD in diseases such as 
Progressive Supranuclear Palsy, Pick’s Disease and other forms of dementia (Ferrer et 
al., 2002; Ferrer et al., 2003). 
 Unlike other members of the cyclin dependent kinase family, Cdk5 is not 
regulated by cyclin expression but is active in post-mitotic neurons because of its 
activators p35/p39 (Liu et al., 2016). These membrane bound activators are prone to 
ubiquitination and degradation leading to short bursts of Cdk5 activity (Liu et al., 2016). 
While active, Cdk5 has been shown to regulate the activity of other kinases including 
GSK3β (Liu et al., 2016). In addition to controlling neurite formation, Cdk5 plays a role 
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in synaptic formation, myelination and maintenance of mitochondrial function (Liu et al., 
2016). In the disease state, prolonged calcium influx leads to calpain mediated cleavage 
of p35 and p39 into their more stable forms p25 and p29 (Lee et al., 2000; Kurbatskaya et 
al., 2016; Liu et al., 2016). The Cdk5/p25 interaction leads to the upregulation of Cdk5 
activity and disease state phosphorylation of APP at threonine 688 (Liu et al., 2016).  
Cdk5/p25 has also been shown to directly affect the cytoskeleton through 
phosphorylation of the WAVE complex, CRMP-2 and MAPs such as Tau (Liu et al., 
2016). In addition to its association with Cdk5, p25 has been shown to bind and 
upregulate GSK3β activity (Chow et al., 2014). 
 The disease state misregulation of signaling as demonstrated by GSK3β and 
Cdk5, does not occur without extracellular cues or other perturbation. For example, 
neurodegenerative diseases such as Alzheimer’s Disease share disease state conditions 
with Diabetes including insulin resistance as the result of chronic metabolic stress and 
inflammation (Liu et al., 2011). It is not clear whether these factors are the cause or result 
of disease state development (Liu et al., 2011). More obvious cause-and-effect examples 
are mutations in proteins such as APP, Presinilin (1 and 2) and Tau (Bull et al., 2012; 
Multhaup et al., 2015; Moustafa et al., 2018). APP is a single pass transmembrane 
protein enriched at synapses (Multhaup et al., 2015). Many functions have been proposed 
for APP including participation in synapse formation, long range signaling and axonal 
transport (Multhaup et al., 2015). As part of its function APP is cleaved by α-, β- and γ-
secretases (Multhaup et al., 2015). In the non-disease state, cleavage by α- and β- 
secretase allows for normal function (Multhaup et al., 2015). APP mutations in secretase 
16 
recognition sites leaves it more vulnerable to disease state γ-secretase cleavage 
(Multhaup et al., 2015).  
The Presinilin genes encode components of the γ-secretase complex which 
participates in the disease state cleavage of APP into the pathogenic peptide Aβ (Hutton 
and Hardy, 1997). Mutations in Presinilin-1 have been proposed to increase γ-secretase 
activity and the generation of Aβ (Hutton and Hardy, 1997; Sun et al., 2017). Tau 
missense mutations can impair microtubule binding and silent mutations affect alternate 
splicing of Tau thereby shifting isoform expression (Yen et al., 1999). Tau plays an 
important role in the regulation of axonal transport and disruption of its functions leads to 
impaired cargo transport (Heins et al., 1991; LaPointe et al., 2009; Kanaan et al., 2012).  
 
1.2 Axonal Transport 
1.2.1 Fast Axonal Transport 
 The first observation of axonal transport was made four decades after Ramón y 
Cajal received his Nobel Prize (Stenoien and Brady, 1999). Experiments by Weiss and 
Hiscoe showed that materials manufactured in the neuronal cell body were essential to 
the maintenance of the axon (Weiss and Hiscoe, 1948). When bulk flow was first 
described, it was found to move at 1-2 mm/day (Stenoien and Brady, 1999). While this 
movement fulfilled some of the requirements for axonal maintenance, it quickly became 
apparent that the slow flow of material could not keep up with the fast signals that were 
known to travel down the axon (Stenoien and Brady, 1999). Twenty years of further 
study showed that a component of this bulk flow moved at much faster rates (up to 400 
mm/day) in both the anterograde and retrograde directions (Stenoien and Brady, 1999).  
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 Fast axonal transport is associated with membrane bound proteins and 
organelles. The size of the transported proteins/organelles has been shown to dictate the 
rate of transport with larger organelles such as mitochondria moving as slow as 50 
mm/day (Stenoien and Brady, 1999). Not even the slowest form of fast axonal transport 
could be explained by the flow of material which governs slow axonal transport. As 
evidence for some directed transport mechanism, it was found that disruption of the 
microtubule network inhibited fast axonal transport (Stenoien and Brady, 1999).  
 By the mid 1980s the idea of motor mediated movement was not new though it 
had yet to be linked to fast axonal transport (Stenoien and Brady, 1999). Muscle myosin 
was first described in 1864 by Wilhelm Kühne (Hartman and Spudich, 2012) and, 
Gibbons and Rowe showed that dynein isolated from cilia had ATPase activity (Gibbons 
and Rowe, 1965). It was known that myosin interacted with actin and dynein with 
microtubules (Stenoien and Brady, 1999). Therefore, in light of the microtubule 
dependence of fast axonal transport it was hypothesized that dynein was involved 
(Stenoien and Brady, 1999). Attempts were made to identify dynein in the brain (Murphy 
et al., 1983) but ATP analog studies showed that a third motor was required for cargo 
transport (Stenoien and Brady, 1999). The inhibitory analog, 5'-adenylyl-
imidodiphosphate (AMP-PNP) has a mild effect on both myosin and dynein but, once 
perfused into squid axoplasm, AMP-PNP completely stopped fast axonal transport (Vale 
et al., 1985; Stenoien and Brady, 1999). This high affinity for the microtubule in the 
presence of AMP-PNP was used to purify the motor now called kinesin (Vale et al., 
1985).  
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1.2.2 Kinesin Motors 
 Experiments in the early 1980s pointed to an as yet unknown ‘translocator’ 
which moved microtubule associated cargo in the axon, specifically squid axoplasm 
(Brady et al., 1982; Allen et al., 1985). Vale purified a novel ATPase from axoplasm and 
bovine brain which was able to slide microtubules in gliding filament assays and move 
beads along microtubules in motility assays (Vale et al., 1985). The word kinesin was 
derived from the Greek kinein (to move) (Vale et al., 1985) and this first kinesin became 
the founding member of a large class of proteins (Hirokawa et al., 2009). 
There are fourteen kinesin families, kinesin-1 through kinesin-14, designated 
based on shared features determined by sequence alignment and phylogenetic analysis 
(Figure 1.5) (Hirokawa et al., 2009). Regardless of family, all kinesins have ATP 
hydrolyzing motor domains and coiled-coil domains which facilitate dimerization (Figure 
1.5) (Vale, 2003; Hirokawa et al., 2009). 
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Figure 1.5: Families and structures of mammalian kinesins. 
a) A phylogenetic tree of all 45 kinesins (KIFs) grouped into 14 families (kinesin-1 to -
14). b) Domain structures of the major kinesins. In general, kinesins comprise a kinesin 
motor domain and a coiled-coil domain. There are also gene specific domains, such as the 
pleckstrin homology (PH), the CAP-Gly domain (a conserved, Gly-rich domain of ~42 
residues found in some cytoskeleton-associated proteins) and WD40 repeats. The 
fourteen families of kinesins can be grouped into N-kinesins, M-kinesins and C-kinesins, 
which contain their motor domain at the amino terminus, in the middle or at the carboxyl 
terminus, respectively. N-kinesins are plus end-directed, C-kinesins are minus end-
directed and M-kinesins depolymerize microtubules. The three types of kinesin are 
grouped as indicated. Figure and legend adapted from Hirokawa et al. (2009). Reprinted 
by permission from Copyright Clearance Center: Springer Nature, Nature Reviews 
Molecular Cell Biology, Kinesin superfamily motor proteins and intracellular transport. 
Hirokawa, N., Noda, Y., Tanaka, Y., and Niwa, S. (2009).  
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 The motor domain position of a kinesin can give some insight into its function. 
Kinesins with N-terminal motor domains are plus end directed, C-terminal motor 
domains are minus end directed and kinesins with motor domains in the middle of their 
sequence act to depolymerize microtubules (Hirokawa et al., 2009). Of the fourteen 
families, there are three major players involved in axonal cargo transport: kinesin-1, -2 
and -3 though kinesin-4 has been found to associate with cargo as well (Hirokawa et al., 
2009).   
 In vertebrates, kinesin-1 is a heterotetramer comprised of two heavy chains 
(kinesin heavy chain, KHC) containing the motor and coiled-coil domains, and two light 
chains (kinesin light chains, KLC) which bind to the C-termini of the KHCs and facilitate 
cargo binding (Vale, 2003). Vertebrates have three KHC genes, two are ubiquitously 
expressed while the third is neuronally expressed (Brady and Morfini, 2017). Two KLCs 
(KLC1 and 2) are neuronally expressed (Brady and Morfini, 2017). Combinations of 
heavy and light chains allow for at least six different kinesin-1 holoenzymes (Brady and 
Morfini, 2017). In addition to different KLCs, a number of adaptor proteins have been 
identified for kinesin-1. They include: Milton and Miro which appear to facilitate 
mitochondrial binding (Wang and Schwarz, 2009), unc-76 from C. elegans (Fasiculation 
and elongation protein zeta 1 (FEZ1) in humans) which allows binding to presynaptic 
vesicles (Toda et al., 2008) and Jun N-terminal kinase (JNK) interacting protein 1 (JIP1) 
which binds to APP transporting vesicles (Inomata et al., 2003).  
 Given the importance of kinesin-1, the motor must be carefully regulated to 
ensure the most efficient delivery of cargo. In addition to autoinhibition, the motor can be 
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regulated by phosphorylation, MAPs and the microtubule track on which it walks 
(Verhey and Hammond, 2009).  
 In the absence of cargo, kinesin-1 is autoinhibited by interactions between the 
motor domain, KHC tail domains and the KLC (Figure 1.6) (Verhey and Hammond, 
2009). The tail domain contains the conserved sequence QIAKPIRP which has been 
shown to interact with the motor domain preventing nucleotide exchange (Figure 1.6) 
(Verhey and Hammond, 2009). Autoinhibition is further regulated by phosphorylation. 
Analytical ultracentrifugation experiments show that JNK3 mediated phosphorylation of 
serine 175 stabilizes kinesin-1’s autoinhibited state (Figure 1.6) (DeBerg et al., 2013). 
Both cargo binding and motor-adaptor protein interactions (FEZ1 and JIP1) have been 
shown to relieve autoinhibition (Figure 1.6) (Verhey and Hammond, 2009).  
Phosphorylation of KLC has also been shown to regulate motor-cargo interactions 
and therefore cargo delivery. There are a number of kinases that act on KLC including 
extracellular-signal regulated kinase (ERK) and GSK3β (Morfini et al., 2002; Vagnoni et 
al., 2011). ERK phosphorylates KLC serine 460 (Figure 6) (Vagnoni et al., 2011). 
Phosphorylation of this site selectively prevents KLC interactions with calsyntenin 1 but 
not other adaptors such as JIP1 (Vagnoni et al., 2011). Calsyntenin 1 is a cadherin-like 
protein which facilitates kinesin-1 interactions with cargo and regulates microtubule 
polarity during axonal development (Lee et al., 2017). Interestingly, adaptor protein 
phosphorylation also regulates interactions with the motor (Figure 1.6) (Chua et al., 
2012). GSK3β is thought to have multiple recognition sites on KLC (Figure 1.6) (Morfini 
et al., 2002). When perfused into the axoplasm, active GSK3β slows anterograde 
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transport (Morfini et al., 2002). Spatial control of kinesin-1 holoenzyme phosphorylation 
regulates both the activation of the motor and its interaction with cargo.  
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Figure 1.6: Kinesin-1 activity is regulated by autoinhibition, phosphorylation and 
adaptor proteins/cargo. 
Kinesin-1 (red/blue) is autoinhibited in a folded conformation though interactions 
between the KHC (red) tail conserved sequence QIAKPIRP and the KLC (blue) with the 
motor domains. Phosphorylation (gray) of the motor domain at serine 175 stabilizes this 
autoinhibited conformation. Phosphorylation of the KLC disrupts interactions with 
specific adaptors. Kinesin-1 autoinhibition can be relieved by dephosphorylation of 
serine 175 and the KLC, cargo binding and/or binding of adaptor proteins (FEZ1 and 
JIP1) to the KLC and KHC respectively. Phosphorylation of adaptor proteins (FEZ1) has 
been shown to facilitate motor-adaptor interactions. Figure and legend created based on 
Morfini et al. (2002), Verhey and Hammond, (2009), Vagnoni et al. (2011), Chua et al. 
(2012) and DeBerg et al. (2013). 
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1.2.3 Neuronal Tubulin 
 Though evidence for microtubules was first found in early electron micrographs, 
it was not till 1963 that they were recognized as distinct structural elements (van de 
Willige et al., 2016). Microtubules are polymers of αβ-tubulin heterodimers that 
assemble to form a hollow tube of on average 13 protofilaments (Yu et al., 2015; van de 
Willige et al., 2016). Both α- and β-tubulin are globular with disorganized, negatively 
charged C-terminal tails (CTT) (Yu et al., 2015). Microtubule polymerization is 
facilitated by β-tubulin GTP binding (Desai and Mitchison, 1997). Tubulin dimers 
polymerize with a fixed α-β polarity and new dimers are added to the β-tubulin end (plus 
end) of the growing microtubule (Figure 1.7) (Geyer et al., 2015; van de Willige et al., 
2016). Microtubules are considered to have dynamic instability because of their ability to 
undergo rapid rounds of growth and shortening (van de Willige et al., 2016). A growing 
microtubule generally has a lattice of predominantly GDP bound dimers and a cap of 
predominantly GTP dimers (Figure 1.7) (Geyer et al., 2015; van de Willige et al., 2016). 
This GTP cap contributes to the stability of the microtubule and GTP hydrolysis in the 
cap is one of the factors that contributes to depolymerization (Desai and Mitchison, 
1997). It has been shown that the nucleotide bound state affects the structure of the 
dimers in the lattice (Geyer et al., 2015). GTP bound tubulin has a compacted α-tubulin 
subunit and GTP hydrolysis relieves this compaction (Geyer et al., 2015). Interestingly, 
some microtubule bound proteins track the GTP cap by recognizing these conformational 
changes (Geyer et al., 2015). 
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Figure 1.7: Tubulin dimer nucleotide exchange and microtubule polymerization. 
A) Both α- and β-tubulin bind GTP however, nucleotide exchange by β-tubulin (in the E 
site) drives microtubule dynamics. B) While GTP is bound to the E site (yellow β-
tubulin), polymerization occurs and as long as the growing microtubule maintains a GTP 
cap growth will continue. GTP hydrolysis (blue β-tubulin) within the lattice is not 
sufficient to lead to catastrophe though this hydrolysis does increase the likelihood of 
lattice defects and once hydrolysis occurs in the GTP cap, catastrophe is inevitable 
(Alushin et al., 2014). Figure and legend adapted from Alushin et al. (2014). Reprinted 
from Cell, 157/5, Alushin, G.M., Lander, G.C., Kellogg, E.H., Zhang, R., Baker, D., and 
Nogales, E., High-resolution microtubule structures reveal the structural transitions in 
alphabeta-tubulin upon GTP hydrolysis, Pages No. 1117-1129, Copyright (2014) with 
permission from Elsevier. 
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As previously discussed, kinesin-1 is regulated by autoinhibition, phosphorylation 
and adaptor protein/cargo binding. However, the microtubule track is itself a major point 
at which regulation of axonal transport takes place. Microtubule polarity ensures that 
kinesin-1 and other major kinesins move cargo towards the synapse (anterograde) while 
the minus end directed motor cytoplasmic dynein moves cargo towards the cell body 
(retrograde) (Stenoien and Brady, 1999).  
 In humans, nine α-tubulin and ten β-tubulin genes have been identified (Aiken et 
al., 2017). In the brain, βIVa is the predominant β tubulin isoform expressed though βIII, 
βIIa and βIIb are also expressed (Leandro-Garcia et al., 2010). βI tubulin is found in all 
tissues (Leandro-Garcia et al., 2010). Of the nine α-tubulin isoforms, α1 and α8 are of 
great importance in neural development and axon growth (Romaniello et al., 2015).   
 In addition to heterodimer diversity, tubulin is subject to a plethora of post 
translational modifications including tyrosination, detyrosination, glutamylation, 
phosphorylation, and glyclation (Figure 1.8) (Yu et al., 2015). These modifications are 
often enriched in different cell types and cell cycle time points (Yu et al., 2015). In the 
growth cone, dynamic microtubules are enriched in tyrosination but the stable 
microtubules of the axon are detyrosinated, acetylated and glutamylated (Yu et al., 2015). 
Tyrosination/detyrosination takes place on α-tubulin CTT (Figure 1.8) (Yu et al., 2015). 
α-Tubulin is initially expressed with a C-terminal tyrosine which can be removed and 
reattached as needed (Yu et al., 2015). Detyrosination exposes a glutamic acid (E-hook) 
and can be made permanent by removal of this E-hook (Yu et al., 2015).  
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In vivo, kinesin-1 has been shown to prefer binding detyrosinated microtubules (Dunn et 
al., 2008). In vitro experiments confirmed this increased affinity along with a slightly 
increased velocity though no change in run length was observed (Kaul et al., 2014).  
 α-Tubulin is also acetylated on its lumenal surface at lysine 40 while β tubulin is 
acetylated at lysine 252 (Figure 1.8) (Yu et al., 2015). In vitro experiments show that 
compared to deactylated microtubules, lysine 40 acetylation does not affect kinesin-1 run 
length, velocity or affinity for the microtubule (Kaul et al., 2014). It is to be noted that 
kinesin-1 does have a longer run length on acetylated versus detyrosinated microtubules 
(Kaul et al., 2014). On acetylated and detyrosinated microtubules as found in the axon, 
kinesin-1 has both increased affinity and run length compared to tyrosinated, deacetylated 
microtubules (Kaul et al., 2014). More recent work suggests that this increased run length 
observed for kinesin-1 on acetylated microtubules is due to increased microtubule 
bundling and therefore kinesin-1 binding site availability (Balabanian et al., 2017). The 
acetylated, detyrosinated microtubules found in the axon enhance kinesin-1 motility 
which in turn allows for more efficient cargo transport. Interestingly, detyrosination has 
been shown to act as an axonal targeting cue for kinesin-1 (Konishi and Setou, 2009). 
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Figure 1.8: Posttranslational modifications of the αβ tubulin heterodimer. 
A. ribbon representation of the tubulin heterodimer (green, α-tubulin; blue, β-tubulin) 
with CTT shown using sequences for the α1A and βIVb tubulin isoforms. Sites of 
acetylation (magenta) and polyamination (dark blue) are shown in stick representation. 
The α-tubulin C-terminal tyrosine (orange) is subject to enzymatic removal 
(detyrosination/tyrosination). Tail glutamates are subject to glutamylation and 
glycylation. B. Zoomed-in view showing the acetylated β-tubulin lysine 252. C. and D. 
view of the α-tubulin (C) and β-tubulin (D) longitudinal interfaces showing the position 
of mapped polyamination sites as dark blue sticks. α-Tubulin lysine 40 is shown in stick 
representation (magenta). Am, amination. Ac, acetylation. Figure and legend adapted 
from Yu et al., (2015) in accordance with the Creative Commons Attribution license. 
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1.2.4 Neuronal MAPs 
 
 Microtubule associated proteins (MAPs) as their name suggests, bind to the 
microtubule cytoskeleton. These proteins include the microtubule tip tracking proteins 
(+TIPs), MAP1, MAP7, MAP2 and MAPT (Tau).  
+TIPs track the growing end of the microtubule. They include the end binding 
proteins (EB 1-3), EB-dependent +TIPs and EB-independent +TIPs (van de Willige et 
al., 2016). EBs track the GTP cap by recognizing structural changes in the tubulin dimer 
upon GTP binding (van de Willige et al., 2016). EB3 is upregulated during neurogenesis 
however, neurite growth and axon formation have been shown to depend on both EB1 
and 3 in neuroblastoma cells and Drosophila (van de Willige et al., 2016). Depletion of 
EB1 in axonal development leads to microtubule splaying and disorganization (van de 
Willige et al., 2016). While tracking the plus end, EBs serve as scaffolds for other +TIPs. 
The higher affinity of EB1/3 for the microtubule has been hypothesized to facilitate 
scaffold maintenance in the growing axon (van de Willige et al., 2016). Proteins that 
scaffold with EB1/3 have conserved binding motifs such as an SxIP (serine/threonine-x-
isoleucine/leucine-proline) or CAP-gly (cytoskeletal-associated protein glycine rich) (van 
de Willige et al., 2016). Proteins with SxIP and CAP-gly sequences participate in the 
maintenance of the axonal cytoskeleton facilitating both anterograde and retrograde 
transport (van de Willige et al., 2016).  
 MAP1 A and B were initially characterized as microtubule stabilizers. Early 
reports suggested that MAP1B localizes to the tips of growing axons (Black et al., 1994).  
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In mouse dorsal root ganglion cells, knock out of MAP1B led to axon turning defects and 
the complete deletion of MAP1B has been shown to prevent development of the corpus 
callosum (Halpain and Dehmelt, 2006). MAP1B is therefore involved in the cytoskeletal 
regulation and axonal development.  
As with the other MAPs above, MAP7 (ensconsin) was first described as a 
microtubule stabilizing protein (Bulinski and Bossler, 1994). Since its characterization, it 
has been demonstrated that MAP7 plays a role in activating kinesin-1 in neurons through 
interactions between the kinesin-1 ‘hinge’ region and MAP7 N-terminal (Barlan et al., 
2013). Though MAP7 activates kinesin-1, it has been shown to inhibit kinesin-3 (Monroy 
et al., 2017). This preferential activation/inhibition further demonstrates the complexity 
of cargo transport regulation. 
Of the MAPs, MAP2 and Tau are the most frequently studied. MAP2 has three 
isoforms (a, b and c) whose expression is developmentally regulated (Tucker et al., 
1988). MAP2c is expressed during development while MAP2a/b are expressed in mature 
neurons (Dehmelt and Halpain, 2005). MAP2c has been shown to be sufficient to induce 
neurite formation (Dehmelt and Halpain, 2005). This is thought to be due to its ability to 
bind both microtubules and actin thereby coordinating microtubule and actin dynamics 
(Dehmelt and Halpain, 2005). As the neuron develops, MAP2 is excluded from the 
forming axon and in mature neurons, MAP2 localizes to dendrites (Dehmelt and Halpain, 
2005). Conversely, Tau is confined to the forming axon and is excluded from dendrites 
(Dehmelt and Halpain, 2005). Both MAP2 and Tau have similar microtubule binding 
repeat regions, have been shown to act as scaffolding proteins and are known to bundle 
microtubules (Dehmelt and Halpain, 2005). The segregation of MAP2 and Tau must 
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therefore relate to their functions in the dendrite and axon respectively. Tau has been 
shown participate in many aspects of axonal transport including the regulation of kinesin-
1 and -3 (Lessard and Berger; Stern et al., 2017). A number of neurodegenerative 
diseases, grouped as Tauopathies, develop due to aberrant expression or regulation of Tau 
within the neuron (LaPointe et al., 2009; Stern et al., 2017; Yin et al., 2017). 
1.3 Tau 
1.3.1 Roles of Tau in Axonal Transport 
 Tau was first identified in 1975 and at the time, it was thought to be a 
microtubule nucleating factor (Weingarten et al., 1975). Later work found that Tau bound 
the microtubule surface with high affinity through a number of microtubule binding 
repeats which each have a weak affinity for the microtubule (Butner and Kirschner, 
1991).  
Since its discovery, Tau has been shown to have many roles beyond microtubule 
nucleation. This includes roles within the axon such as regulation of microtubule 
dynamics, participation in signaling cascades and inhibition of kinesin-1 motility (Stern 
et al., 2017). While Tau is generally thought to stabilize microtubules, its function in the 
regulation of microtubule dynamics is more complex. Work done by Panda et al. shows 
that Tau affects specific aspects of microtubule growth and shortening (Panda et al., 
2003). 4RL-Tau reduces the rate of shortening while 3RL-Tau has no effect (Panda et al., 
2003). However, both isoforms increase microtubule growth and reduce dynamicity 
(Panda et al., 2003).  
 Tau participates in signaling cascades in a number of ways. Tau has been shown 
to inhibit the deacetylation activity of histone deacetylase 6 (HDAC6) which acts on 
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microtubules (Perez et al., 2009). Additionally, Tau’s phosphatase activating domain 
(PAD) has been shown to play a role in the regulation of bulk cargo movement through 
the axon (LaPointe et al., 2009). The PAD has been shown to act in the activation of the 
protein phosphatase 1 (PP1) which in turn leads to the activation of GSK3β (Morfini et 
al., 2002; Kanaan et al., 2011; Kanaan et al., 2012). Outside of the axon in the dendrite, 
Tau acts as a scaffolding protein to mediate the interaction between Fyn kinase and post 
synaptic density 95 (PSD95) in the disease state (Ittner et al., 2010). This interaction 
leads to the phosphorylation and toxic activation of the N-methyl-D-aspartate (NMDA) 
receptor (Ittner et al., 2010). In addition to all of the above roles, Tau has been found in 
the nucleus where it is thought to protect DNA (Sultan et al., 2011). 
1.3.2 Regulation of Tau Isoform Expression 
 There are six human Tau isoforms (Figure 1.9) which arise from the alternative 
splicing of a single Tau gene on chromosome 17 (Andreadis, 2005). All the isoforms 
have a PAD and proline rich region (PRR) while isoforms differ based on number of 
acidic inserts (0-2) and microtubule binding repeats (3-4) (Figure 1.9) (Stern et al., 2017). 
In the mapT gene, exon 10 encodes the second microtubule binding repeat and regulation 
of exon 10 inclusion controls 3 repeat (3R)- versus 4R-Tau isoform expression. This 
regulation occurs developmentally and 3R isoforms are exclusively expressed in the 
developing brain. In the adult brain 3R and 4R isoforms are expressed equally 
(Andreadis, 2005; Yin et al., 2017). Splicing of exons 2 and 3 controls the number of 
acidic inserts (AI) and give rise to short (0 AI), intermediate (1 AI) and long (2 AI) 
isoforms (Yin et al., 2017).  
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Acidic Inserts Microtubule Binding Repeats 
Proline Rich Region Phosphatase Activating 
Domain 
4RL-Tau 
3RL-Tau 
4RM-Tau 
3RM-Tau 
4RS-Tau 
3RS-Tau 
Figure 1.9 Tau isoforms. 
Six Tau isoforms are expressed in the adult brain as the result of alternative splicing 
of the gene mapT (Ballatore et al., 2007). All isoforms have a phosphatase activating 
domain (purple) and a proline rich region (blue). The isoforms differ based on 
number of acidic inserts (green; 0, 1 or 2) and microtubule binding repeats (red; 3 or 
4). Inclusion of acidic inserts and the second microtubule binding repeat is regulated 
by alternative splicing of exons 2, 3 and 10. Figure and legend based on Ballatore et 
al., (2007).  
34 
 
The regulation of exon 10 splicing is critically important for the maintenance of 
the neuron. Defects in exon 10 splicing lead to shifts in the ratio of 3R vs 4R Tau isoform 
expression (Yin et al., 2017). In frontotemporal dementia with Parkinsonism linked to 
chromosome 17 (FTDP-17), mutations in the Tau gene result shifts in 3R or 4R isoform 
expression (Yin et al., 2017). In Down Syndrome, trisomy of chromosome 21 leads to the 
overexpression of the kinase dual-specificity tyrosine-phosphorylated and regulated 
kinase 1A (Dyrk1A) (Yin et al., 2017). Dyrk1A has mainly nuclear expression and has 
been shown to co-localize with splicing factors (Yin et al., 2017). Furthermore Dyrk1A 
phosphorylates serine/arginine rich factor 55 (SRp55) (Yin et al., 2017). SRp55 has been 
shown to regulate the inclusion of exon 10 (Yin et al., 2012; Qian et al., 2013). SRp55 
promotes exon 10 inclusion and phosphorylation by Dyrk1A leads to down regulation of 
SRp55 activity and increased 3R-Tau expression (Yin et al., 2017). Alternatively, 
inhibition of Dyrk1A leads to increased 4R-Tau expression (Yin et al., 2017). In AD, 
calpain activation has been shown lead to increased Dyrk1A cleavage at the C-terminus 
(Jin et al., 2015). This leads to increased Dyrk1A activity which is correlated with shifts 
in isoform expression (Jin et al., 2015). During mouse development, Dyrk1A expression 
has been shown to decrease from postnatal day (P) 5 to P35 corresponding with a shift 
from 3R to 4R isoform expression (Yin et al., 2017).  
 Dyrk1A action is not the only means by which Tau isoform expression is 
regulated. Transactive DNA-binding protein of 4 kDa (TDP-43) has been shown to 
promote exon 10 inclusion (Gu et al., 2017). Interestingly, TDP-43 has been shown to 
aggregate in the cytoplasm of AD patients (Gu et al., 2017). Unlike Dyrk1A activity, 
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increased TDP-43 activity leads to increased 4R isoform expression (Gu et al., 2017). 
Shifts of to either extreme of isoform expression are detrimental for the cell and are a 
hallmark of disease development.  
1.3.3 Post-translational Modifications of Tau 
 Tau is subject to a number of post-translational modifications (PTMs) including 
methylation, acetylation, ubiquitination, O-GlcNacylation and phosphorylation (Figure 
1.10) (Morris et al., 2015). Of these PTMs, phosphorylation is the most abundant though 
work has been done with acetylation and its role in disease state development (Cohen et 
al., 2011; Morris et al., 2015; Carlomagno et al., 2017). Acetylation has been shown to 
inhibit Tau-microtubule interactions and promote filament formation (Cohen et al., 
2011). Recently, disease state acetylation of lysine 321has been shown to promote 
phosphorylation of serine 324 (Carlomagno et al., 2017). This link between PTMs 
highlights the need to further study non-phosphorylation PTMs in Tau function.  
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Figure 1.10 Domain structure of 4RL-Tau showing the positions of many PTMs.  
Tau is an incredibly modified protein with 85 proposed or identified phosphorylation 
sites. Figure and legend adapted from Morris et al. (2015). Reprinted by permission from 
Copyright Clearance Center: Springer Nature, Nature Neuroscience, Tau post-
translational modifications in wild-type and human amyloid precursor protein transgenic 
mice, Morris, M., Knudsen, G.M., Maeda, S., Trinidad, J.C., Ioanoviciu, A., Burlingame, 
A.L., and Mucke, L. (2015). 
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As the most abundant PTM, it is not surprising that Tau has 85 proposed or 
identified phosphorylation sites (Martin et al., 2013b). Most of these sites have been 
identified in the disease state and cluster around the proline rich region and MBRs 
(Martin et al., 2013b). It has been shown that phosphorylation in and around the MBR 
reduces Tau’s affinity for the microtubule surface (Biernat et al., 1993). As indicated by 
the large number of phosphorylation sites, Tau is phosphorylated by a number of kinases. 
These include the serine/threonine kinases GSK3β, CDK5, PKA and the tyrosine kinases 
Fyn, Lck and Abl (Martin et al., 2013b).  
 Initially, GSK3β was thought to be Tau protein kinase 1 before Ishiguro proved 
that these kinases were identical (Ishiguro et al., 1993). Both GSK3β and CDK5 
phosphorylate Tau at many serine/threonine sites including serine 202/threonine 205 
(widely known as the AT8 epitope) (Goedert et al., 1995; Wada et al., 1998). Disease 
state phosphorylation is exacerbated by the fact that phosphorylation by one kinase 
primes other sites (Hanger and Noble, 2011). For example, priming phosphorylation of 
serine 235 and serine 404 by CDK5 and other kinases, allows GSK3β to phosphorylate 
Tau at serine 396 and serine 400 (Hanger and Noble, 2011). PKA phosphorylation also 
serves to prime GSK3β sites (Hanger and Noble, 2011). PKA phosphorylation of serine 
214 allows GSK3β phosphorylation of serines 175, 199, 210 and threonine 205 (Hanger 
and Noble, 2011). This paints a complex picture of hyperphosphorylation which requires 
the coordinated action of multiple misregulated kinases.  
 The Src family kinases have been shown to phosphorylate Tau at all five 
tyrosines (18, 29, 197, 310 and 394) (Lee et al., 1998; Martin et al., 2013b). The 
interactions between Tau and these kinases occur away from the microtubule surface 
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because Src family kinases are membrane anchored (Lee et al., 1998). PXXP motifs in 
Tau’s proline rich region, allow interactions with Src homology 3 domains (Lee et al., 
1998). Of the Src kinases that phosphorylate Tau, Fyn is of interest because it has been 
shown to predominantly phosphorylate Tau at tyrosine 18 (Y18). Both Tau and Fyn are 
present in the developing axon and the loss of Fyn leads to loss of axon extensions in Fyn 
knockout mice (Lee et al., 1998). Fyn is itself subject to phosphorylation on tyrosine 
residues (Vacaresse et al., 2008). Tyrosine phosphorylation in the C-terminal inhibits Fyn 
activity while auto-phosphorylation at tyrosine 416 and the action of protein tyrosine 
phosphatase to remove the inhibitory phosphorylation in response to external growth 
cues, activates the kinase and allows it to then phosphorylate Tau and other targets 
(Vacaresse et al., 2008). Tau Y18 is phosphorylated in both the disease and non-disease 
states (Lee et al., 1998; Martin et al., 2013b) and Fyn has been shown to associate with 
neurofibrillary tangles in the disease state (Lee et al., 2004). The case of tyrosine 18 
phosphorylation is unique because of it has been shown to shield the PAD in the disease 
state (Kanaan et al., 2012) and to potentially stabilize a non-disease sate, solution based 
dynamic folded conformation of Tau (Jeganathan et al., 2006).  
 Tau regulates axonal transport in a number of ways (discussed above) including 
through participation in signaling cascades. Signaling cascade participation is mediated 
by Tau’s PAD domain which has been shown to participate in the activation of GSK3β 
(Kanaan et al., 2012). Tyrosine 18 is the last residue in the PAD and its phosphorylation 
prevents Tau from participating in GSK3β activation (Kanaan et al., 2012). In fact, the 
PAD fragment has been shown to inhibit the bulk flow of cargo in the axoplasm while 
tyrosine 18 phosphorylated PAD did not have the same effect (Kanaan et al., 2012) 
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highlighting a role for non-disease state phosphorylation events in the maintenance of 
axonal transport.  
 As with all phosphorylation events, Tau phosphorylation is antagonized by the 
action of phosphatases. These include, PP1, protein phosphatase 2A (PP2A) and protein 
tyrosine phosphatases (Martin et al., 2013a). These phosphatases control the action of the 
kinases that phosphorylate Tau as well as the phosphorylation of Tau itself (Martin et al., 
2013a). In the disease state, phosphatase activity is greatly reduced further exacerbating 
the activity of the kinases which ultimately phosphorylate Tau (Martin et al., 2013a). 
1.3.4 Tau and Kinesin 
 MAP inhibition of motor motility was first demonstrated in 1989 (von Massow 
et al., 1989). In 1991, Heins et al. showed that both MAP2 and Tau inhibited kinesin 
dependent motility (Heins et al., 1991). This gave rise to a model where Tau and other 
MAPs act as obstacles for kinesin thereby reducing kinesin runlength (Seitz et al., 2002). 
TIRF assays showed that this was indeed the case as both MAP2 and Tau inhibited 
kinesin runlength (Seitz et al., 2002). These results agreed with previous work 
demonstrating that over expression of Tau in neuronal cell lines inhibits movement of 
kinesin cargo (Ebneth et al., 1998). Interestingly, TIRF assays performed by Seitz et al. 
showed differences in tau isoform inhibition where 3RS-Tau was more inhibitory then 
4RL-Tau (Seitz et al., 2002).  
 Reports of MAP-motor inhibition suggested that both kinesin and dynein were 
inhibited by Tau (Trinczek et al., 1999). However, more recent work demonstrated that 
both 3RS- and 4RL-Tau inhibited kinesin-1 at multiple concentrations while kinesin-2 
and dynein were not affected (Dixit et al., 2008; Hoeprich et al., 2014). This work 
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showed Tau’s preferential inhibition of kinesin-1 motility. TIRF assays also 
demonstrated Tau patch formation i.e. cooperative binding on the microtubule surface in 
accordance with earlier work (Ackmann et al., 2000; Dixit et al., 2008).  
 Highlighting the interconnectivity of the axonal transport system, in addition to 
Tau isoform differences, the microtubule lattice has been shown to affect the isoforms’ 
ability to inhibit kinesin-1 (McVicker et al., 2011). McVicker et al. (2011) showed that 
both 3RS- and 4RL-Tau inhibition of kinesin-1 motility was reduced on GMPCPP 
microtubules compared to paclitaxel stabilized microtubules. Additionally complicating 
the idea of Tau inhibition, increases in motor velocity were observed in the presence of 
both isoforms though kinesin-1 showed a greater increase in velocity in the presence of 
4RL-Tau on paclitaxel stabilized microtubules (McVicker et al., 2011). This paints a 
picture of Tau isoform and microtubule lattice regulation instead of straight inhibition of 
kinesin-1 motility. 
 For twenty-three years it was thought that Tau and other MAPs were immobile 
while bound to the microtubule (Ackmann et al., 2000; Dixit et al., 2008). However, 
further work showed that Tau is able to bind both statically and diffusively to the 
microtubule surface (Figure 1.11) (Hinrichs et al., 2012). This study highlighted a 
possible mechanism by which the high concentrations of Tau found in the axon do not 
impede cargo delivery in non-disease state conditions. However, it did not explain the 
differences in Tau isoform ability to regulate kinesin-1 motility. 
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Figure 1.11 Tau diffuses along the microtubule surface. 
A) Frames of a labeled 4RL-Tau molecule (green) moving along a Cy5-labeled 
microtubule (red) in the absence of ATP. Time intervals were as indicated. B) 
Kymograph showing the diffusive behavior of the event pictured in A. Figure and 
legend adapted from Hinrichs et al., (2012) in accordance with the Creative 
Commons Attribution license. 
. 
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Furthering the observation that Tau binds the microtubule in a static-diffusive 
state equilibrium, 3RS- and 4RL-Tau were observed to have different binding equilibria 
(McVicker et al., 2014). 3RS-Tau binds more statically that 4RL-Tau on paclitaxel 
microtubules (McVicker et al., 2014). This suggested that 3RS-Tau was more inhibitory 
to kinesin-1 because of its shift towards static binding. This hypothesis was further 
supported when both isoforms were observed to shift towards diffusive binding on 
GMPCPP microtubules where previous work demonstrated that Tau is less inhibitory to 
kinesin-1 motility (McVicker et al., 2014).  
While this work takes into account the nucleotide bound state of the lattice, 
questions remain about the involvement of lattice and Tau PTMs in the regulation of Tau 
behavior. Recent work has begun to answer these questions. Non-disease state 
phosphorylation of tyrosine 18 has been shown to regulate 3RS-Tau’s binding 
equilibrium (Stern et al., 2017). Work with acetylation demonstrated that Tau is 
insensitive to this microtubule PTM though it was observed to favor highly curved 
microtubule sections (Balabanian et al., 2017).  
1.3.5 Tau Structure 
 In 1975 when Tau was first identified, it was found to be heat stable 
(Weingarten et al., 1975). This property surprised the authors at the time and was the first 
identification that Tau did not have a tertiary structure. Circular dichroism assays 
comparing Tau to myoglobin revealed that Tau had no significant α-helical or β-sheet 
structure confirming the 1975 observations (Cleveland et al., 1977). Almost upon 
discovery, the challenge to understand Tau structure was made apparent.   
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By 1988, neuronal microtubules had been observed to have crosslinks comprised 
of MAP1 and MAP2 but the structure of Tau remained unknown though its role in the 
disease state was firmly established (Hirokawa et al., 1988). Deep-etch cryo-EM studies 
showed that a portion of the Tau molecule extends away from the microtubule surface 
(Hirokawa et al., 1988). Other cryo-EM studies that did not rely on pelleting, showed that 
Tau bound to microtubules results in a ‘fuzzy’ microtubule coating (Al-Bassam et al., 
2002; Santarella et al., 2004). These studies used helical reconstruction and Tau labeling 
techniques to determine that Tau binds along protofilament ridges potentially with 
binding sites at the α-tubulin subunits (Al-Bassam et al., 2002; Santarella et al., 2004). 
Current work by the Nogales group, refines previous cryo-EM work confirming Tau 
binding on microtubule protofilaments with microtubule binding repeats binding in 
tandem (Kellogg et al., 2018). This binding occurs along tubulin heterodimers (Kellogg 
et al., 2018) and explains Tau’s ability to regulate microtubule dynamics by crosslinking 
dimers. Together, these studies elucidate Tau structure though none of these studies 
account for the dynamic structural changes which the ‘fuzzy’ microtubule coat indicates.  
In addition to the investigation of Tau’s bound structure, solution based study of 
Tau confirmation using NMR, bulk FRET and single molecule FRET studies, show that 
Tau has a dynamic folded confirmation (Figure 1.12) (Jeganathan et al., 2006; Elbaum-
Garfinkle and Rhoades, 2012).  These two studies differ in their placement of the N- and 
C-termini relative to the MBRs though they both agree in the folded nature of Tau in 
solution (Figure 1.12) (Jeganathan et al., 2006). Further work with disease state 
phosphorylation events showed compaction of Tau’s solution based folded confirmation 
(Jeganathan et al., 2008). 
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Figure 1.12 Structures of Tau in solution. 
Tau has been shown to have a dynamic folded conformation in solution. A) NMR and 
bulk FRET studies were used to generate this paperclip-like folded conformation where 
the C-terminal interacts with the microtubule binding repeats and the N-terminal. The 
overall conformation is stabilized by interactions between the N- and C-termini. Figure 
and legend reprinted with permission from Jeganathan, S., von Bergen, M., Brutlach, H., 
Steinhoff, H.J., and Mandelkow, E. (2006). Global hairpin folding of tau in solution. 
Biochemistry 45, 2283-2293. Copyright (2006) American Chemical Society. B) Single 
molecule solution based FRET was used to generate this conformation of Tau in the 
absence of heparin (watermark) where both the N- and C-termini interact with the 
microtubule binding repeats to stabilize this folded conformation. In the presence of 
heparin, which promotes Tau aggregation, these interactions are greatly reduced. Figure 
and legend reprinted with permission from Elbaum-Garfinkle, S., and Rhoades, E. 
(2012). Identification of an aggregation-prone structure of tau. J. Am. Chem. Soc. 134, 
16607-16613. Copyright (2012) American Chemical Society. 
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The studies of Tau structure to date, have elucidated our understanding of Tau 
structure both on and off the microtubule surface. However, many questions remain 
including whether structural changes on the microtubule surface underlie Tau’s binding 
behavior and ability to inhibit kinesin-1 motility. The work presented in this dissertation 
represents a first attempt at linking Tau structural change to its behavior on the 
microtubule surface and regulation of motor motility.  
1.4 Purpose and Scope 
One hundred and twelve years have passed since Santiago Ramón y Cajal gave his 
acceptance speech in 1906. Over that time, the field has progressed in its understanding 
of the neuron and the processes that ensure neuronal function. Despite the strides that 
have been made, many questions remain open. One of the most basic and fascinating, is 
the means by which cellular material manufactured in the cell body is moved throughout 
the axon. This processes of axonal transport is a complex system of motors, microtubule 
tracks and regulators that in the largest axon can stretch up to 2 meters (Britannica, 
2018). During axonal development and throughout the life of the cell, Tau plays an 
integral role in the regulation of this system (Figure 1.13). As described in the preceding 
text, the signaling pathways that regulate axonal development and function converge on 
the cytoskeletal elements involved in axonal transport. The regulation of axonal transport 
is complex involving inter-play between the tracks, the motors and the microtubule 
associated proteins. Of the microtubule associated proteins, Tau has been extensively 
studied because of its involvement in transport regulation (Figure 1.13) throughout the 
life of the cell and in disease development.  
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Figure 1.13: Tau Functions in Axonal Transport 
Tau has been shown to regulate axonal transport in a number of ways. A) Tau 
isoforms differentially regulate microtubule growth and shortening (Panda et al., 
2003). B) Tau has also been shown to participate in signaling cascades. The PAD has 
been shown to activate PP1 which in turn activates GSK3β. Activation of GSK3β, 
leads to the phosphorylation of kinesin-1 light chains and the release of cargo (Morfini 
et al., 2002; LaPointe et al., 2009). The PAD is shielded by tyrosine 18 (Y18) 
phosphorylation (Kanaan et al., 2012). In the disease state, PAD shielding by Y18 
phosphorylation prevents inhibition of axonal transport. C) Tau has been shown to 
preferentially inhibit kinesin-1 motility in vitro (Dixit et al., 2008). This inhibition 
does not disrupt cargo transport in vivo and raises the question of whether Tau is 
regulated on the microtubule and how this regulation affects motor motility. The work 
presented here focusses on cellular regulation of Tau’s structure and function by 
phosphorylation and the role this may play in motor motility regulation. 
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Since Tau was identified as a regulator of kinesin-1 motility (Heins et al., 1991), 
efforts have been made to understand the means by which this regulation occurs and how 
the cell controls this regulation (Ebneth et al., 1998; Trinczek et al., 1999; Seitz et al., 
2002). Counterintuitively, though Tau has been shown to inhibit kinesin-1 motility in 
vitro in a concentration dependent manner (Dixit et al., 2008), cargo transport is not 
inhibited by the high concentration of Tau (2-5 µM) found in the axon (Morfini et al., 
2007; Avila, 2010). This apparent disagreement between in vitro and in vivo observations 
raises the question of how the cell regulates motor motility inhibition to allow for cargo 
delivery in non-disease state conditions. In partial answer to this question, Tau has been 
shown to bind the microtubule in a static-diffusive state equilibrium, which differs with 
isoform and lattice, and corresponds with isoform ability to inhibit kinesin-1 motility 
(Dixit et al., 2008; McVicker et al., 2011; Hinrichs et al., 2012; McVicker et al., 2014). 
These studies do not explain the purpose of the static-diffusive state binding equilibrium 
and do not show how this equilibrium is regulated. The work presented here aims to fill 
this gap in our knowledge so that we can begin to understand how regulation of Tau’s 
static-diffusive state equilibrium allows for cellular regulation of axonal transport.  
In vitro work studying Tau microtubule binding behavior and motor motility 
inhibition uses recombinant human Tau expressed in bacterial systems (Dixit et al., 2008; 
McVicker et al., 2014). This method of expression does not allow Tau to be post-
translationally modified as it would be within the cell. Tau is subject to an incredible 
number of post-translational modifications including 85 proposed or identified 
phosphorylation events (Martin et al., 2013b). It is therefore not inconceivable that 
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phosphorylation may play a role in the regulation of Tau function. In fact, it has been 
shown that phosphorylation of tyrosine 18 prevents Tau disease state inhibition of axonal 
transport (Kanaan et al., 2012). These results made tyrosine 18 an interesting target to 
explore in the regulation of Tau behavior on the microtubule surface. In chapter two, we 
address the question of how tyrosine 18 phosphorylation affects Tau’s ability to inhibit 
kinesin-1 motility. We demonstrate that phospho-mimetics of tyrosine 18 in 3RS-Tau 
exhibit a shift in static-diffusive state equilibrium towards the diffusive state, correlating 
with a reduction in inhibition of kinesin-1 motility. We further demonstrate that the 
static-diffusive state binding equilibrium is maintained ex vivo, as is the phosphorylation 
mediated diffusive state shift. This work represents the first demonstration of a means by 
which the cell can regulate Tau’s binding equilibrium. Furthermore, this is the first 
evidence that Tau’s static-diffusive state equilibrium is maintained under physiological 
conditions highlighting a role for static and diffusive binding in Tau’s cellular function. 
While chapter 2 highlights the importance of regulating Tau’s binding equilibrium, it 
also raises more questions about microtubule bound Tau. Tyrosine 18 phosphorylation is 
an N-terminal modification. The N-terminal of Tau does not interact with the microtubule 
surface (Goode et al., 2000), however, our results from chapter 2 demonstrate that 
phosphorylation of tyrosine 18 affects Tau binding behavior. This indicates that tyrosine 
18 phosphorylation potentially affects Tau binding through long range structural change. 
Interestingly, in addition to regulating Tau’s static-diffusive state equilibrium, tyrosine 18 
has been implicated in the stabilization of a solution based dynamic folded conformation 
of Tau (Jeganathan et al., 2006).  
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Admittedly, studying Tau’s conformation is challenging because it has no tertiary 
structure (Cleveland et al., 1977). Solution based structural studies have shown that Tau 
has a dynamic folded conformation (Jeganathan et al., 2006; Elbaum-Garfinkle and 
Rhoades, 2012). However, these techniques have not been used to identify dynamic 
structural changes on the microtubule surface. Cryo-EM studies have attempted to 
visualize microtubule bound Tau and while they have had success resolving portions of 
the protein, they cannot be used to study dynamic structural changes (Hirokawa et al., 
1988; Al-Bassam et al., 2002; Santarella et al., 2004; Kadavath et al., 2015; Kellogg et 
al., 2018). The ‘fuzzy’ Tau coated microtubules that have been seen with cryo-EM do 
however support the idea of dynamic structural change (Al-Bassam et al., 2002; 
Santarella et al., 2004). Recent cryo-EM work has been able to show the interactions of 
microtubules with microtubule binding repeats while Tau is bound statically (Kellogg et 
al., 2018). These structures have higher resolution than previous work and confirm that in 
the static state Tau binds along the protofilament with fully extended microtubule binding 
repeats (Kellogg et al., 2018). While this study does not resolve Tau’s N- and C-termini 
or the microtubule binding repeats in the diffusive state, it give us questions for future 
study.  
In chapter 3, we hypothesize that distinct structural changes underlie static versus 
diffusive binding. Instead of solution or cyro-EM based studies, we use a three color 
single molecule fluorescence resonance energy transfer assay imaging with total internal 
reflection fluorescence microscopy and alternating laser excitation (ALEX) to show that 
in the static state the N- and C- termini of Tau interact more closely than in the diffusive 
state. Our assay allows us to observe dynamic structural changes while Tau is bound to 
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the microtubule. The results indicate that there are indeed distinct structural changes that 
underlie Tau’s binding equilibrium. Prior to this work, no studies have been done to 
elucidate what structural changes underlie the static-diffusive binding equilibrium and 
therefore Tau’s behavior and function on the microtubule surface. 
Taken together, these studies demonstrate the link between structure and function of 
Tau and the cellular means by which Tau behavior and function can be regulated. While 
we have begun to address the link between Tau structure and function on the microtubule 
surface, this work also points to new questions that must be answered. In chapter 4, I 
outline our work in the context of the field and provide directions that the techniques we 
have developed now allow us to take. 
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CHAPTER 2: PHOSPHO-REGULATION OF TAU MODULATES KINESIN-1 
MOTILITY 
2.1 Abstract 
Microtubule-based axonal transport is tightly regulated by numerous pathways 
ensuring appropriate delivery of specific organelle cargoes to selected subcellular 
domains. Highlighting the importance of this process, pathological evidence has linked 
alterations in these pathways to the pathogenesis of several neurodegenerative diseases. 
An important regulator of this system, the microtubule associated protein Tau has been 
shown to participate in signaling cascades, modulate microtubule dynamics and 
preferentially inhibit kinesin-1 motility. However the cellular means of regulating Tau’s 
inhibition of kinesin-1 motility remains unknown. Tau is subject to various post-
translational modifications including phosphorylation, but whether phosphorylation 
regulates Tau on the microtubule surface has not been addressed. It has been shown that 
tyrosine 18 phosphorylated Tau regulates inhibition of axonal transport in the disease 
state. Tyrosine 18 is both a disease and non-disease state modification and is therefore an 
attractive starting point for understanding control of Tau’s inhibition of kinesin-1 
motility. We show that pseudophosphorylation of tyrosine 18 reduces 3RS-Tau’s 
inhibition of kinesin-1 motility. Additionally, we show that introduction of negative 
charge at tyrosine 18 shifts Tau’s previously described static-dynamic state binding 
equilibrium towards the dynamic state. We also present the first evidence of the 
establishment of Tau’s static-dynamic state equilibrium under physiological conditions. 
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2.2 Introduction 
The neuronal microtubule associated protein (MAP) Tau is involved in axonal 
development from its earliest stages onwards (Andreadis, 2005). Tau has been implicated 
in many processes within the neuron, the majority of which are associated with its 
participation in axonal transport (AT). The AT system encompasses the microtubule 
track, molecular motors including kinesin-1 and -2, numerous MAPs including Tau, and 
many signaling cascades (Maday et al., 2014). Tau’s role in AT is multi-faceted, as it has 
been shown to stabilize microtubules (Panda et al., 2003), participate in signaling 
cascades (Kanaan et al., 2012) and inhibit kinesin-1 motility (Vershinin et al., 2007; 
Dixit et al., 2008; McVicker et al., 2011). In the non-disease state Tau’s ability to 
preferentially inhibit kinesin-1 motility is of particular interest when juxtaposed with the  
failure of this inhibition to disrupt normal cargo delivery, suggesting that Tau has a role 
in the modulation of kinesin-mediated cargo delivery during AT (Kanaan et al., 2012). 
This highlights the importance of cellular regulation of Tau’s inhibitory function of 
kinesin-1 transport during AT, but how this control is achieved is currently unknown.  
Understanding Tau’s function and corresponding regulation is compounded by its 
sequence diversity. There are six Tau isoforms which arise from strict developmental 
regulation of the alternative splicing of the MAPT gene on chromosome 17 (Andreadis, 
2005; Ballatore et al., 2007). While all six isoforms have a central proline rich region 
(PRR) and N-terminal phosphatase activating domain (PAD) (Ballatore et al., 2007; 
Kanaan et al., 2012), they differ by number of C-terminal microtubule binding repeats 
(three – four) and N-terminal acidic inserts (zero – two) (Goode et al., 2000; Ballatore et 
al., 2007). Tau’s role in signaling is partly mediated by its PAD which has been shown to 
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activate protein phosphatase 1 (PP1) (LaPointe et al., 2009; Kanaan et al., 2011). In the 
disease state, a phospho-mimetic of tyrosine 18 (Y18), the last residue in the PAD, has 
been shown to prevent the inhibition of axonal transport when incorporated into 
neurofibrillary tangles (Kanaan et al., 2012). Y18 is predominantly phosphorylated by the 
Src family kinase Fyn in both the disease and non-disease states (Lee et al., 1998; 
Kanaan et al., 2012; Larson et al., 2012).  
Adding to this isoform diversity, it has recently been shown that Tau can bind the 
microtubule in an equilibrium between static and ATP-independent dynamic states 
(Vershinin et al., 2007; Dixit et al., 2008; Hinrichs et al., 2012). We have shown that the 
static-dynamic state equilibrium differs with Tau isoform and microtubule lattice 
structure with the shortest isoform, 3RS-Tau, being more static on paclitaxel stabilized 
microtubules than the longest isoform, 4RL-Tau (McVicker et al., 2014). Tau’s ability to 
inhibit kinesin-1 motility also differs with isoform. 3RS-Tau, which favors the static 
state, is more inhibitory to kinesin-1 than 4RL-Tau (Dixit et al., 2008; McVicker et al., 
2011). This correlation indicates that the static state is more inhibitory to kinesin-1 
motility than the dynamic state. Given these isoform-specific differences in behavior, a 
common mechanism for regulating multiple Tau isoforms and their static-dynamic state 
equilibria remains unclear.  
All isoforms of Tau are subject to a variety of post-translational modifications 
(Watanabe et al., 1993; Funk et al., 2014; Kamah et al., 2014) which may have important 
roles in many aspects of Tau regulation. We postulate that post-translational 
modifications (especially phosphorylation) are the link between controlling Tau’s static-
dynamic equilibrium and Tau’s inhibition of kinesin-1 motility. As stated above, static 
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Tau is more inhibitory to kinesin-1 motility than dynamic Tau (McVicker et al., 2011) 
while phosphorylation/a phospho-mimetic of Y18 has been shown to prevent inhibition 
of axonal transport in the disease state (Kanaan et al., 2012). We hypothesize that the 
negative charge provided by phosphorylation of Y18 stabilizes the dynamic 
state/destabilizes the static state thereby shifting the static-dynamic equilibrium towards 
the less inhibitory dynamic state. To test this hypothesis, we generated phospho-mimetic 
and control 3RS-Tau constructs by mutating Y18 to glutamic acid (Y18E 3RS-Tau) and 
alanine (Y18A 3RS-Tau). To study the effect of increasing the negative charge at/around 
Y18, a double phospho-mimetic was generated by mutating threonine 17 and Y18 to 
glutamic acid (dE 3RS-Tau). Using total internal reflection fluorescence (TIRF) 
microscopy, we observed single molecule 3RS-Tau interactions with paclitaxel stabilized 
microtubules. Our results provide the first evidence for direct control by phosphorylation 
of Tau’s dynamic behavior, and therefore its function, on the microtubule surface. 
2.3 Results 
Introduction of negative charge at Y18 reduces 3RS-Tau inhibition of kinesin-1 motility. 
TIRF microscopy was used to visualize kinesin-1 motility (Figure 2.1) on paclitaxel 
stabilized microtubules in the presence of  200 nM unlabeled and Alexa 488 labeled WT 
and Y18E 3RS-Tau (1:5; Tau:tubulin) (Figure 2.2A). In the absence of Tau, kinesin-1 
had a run length of 1.64  0.50 µm (Figure 2.2B) which was significantly decreased in 
the presence of both unlabeled and labeled WT 3RS-Tau (0.99  0.23 µm and 0.99  
0.24 µm; Figure 2.2, C and D; Supplemental Table S2.2; Supplemental Figure S2.1) as 
we have previously demonstrated (McVicker et al., 2011). Interestingly however, 
kinesin-1’s run length significantly increased in the presence of Y18E 3RS-Tau 
55 
(unlabeled = 1.37  0.39 µm, labeled = 1.35  0.39 µm; Figure 2.2, E and F) compared 
to the WT 3RS-Tau condition (Figure 2.2, C and D). Kinesin-1’s velocity did not differ 
under any of the conditions tested (Supplemental Table S2). These results indicate that 
introduction of negative charge at Y18 reduces 3RS-Tau’s inhibition of kinesin-1 run 
length without affecting its velocity. WT Tau’s ability to inhibit kinesin-1 run length 
without affecting velocity has been reported previously (Dixit et al., 2008). This is the 
first evidence for phosphorylation mediated regulation of 3RS-Tau’s ability to inhibit 
kinesin-1 motility.  
A Y18 phospho-mimetic of 3RS-Tau exhibits a significant shift towards the dynamic state 
in vitro. Given the results of our motility assays, we wanted to know if the introduction of 
negative charge at Y18 affects Tau’s static-dynamic equilibrium on the microtubule 
surface. TIRF microscopy was used to visualize the interactions of the constructs used in 
the motility assays (WT and Y18E 3RS-Tau) (Figure 2.3A) with TRITC rhodamine 
labeled paclitaxel stabilized microtubules at 200 nM Tau (1:5, Tau:tubulin). We observed 
predominantly static events for WT 3RS-Tau (77.1 ± 4.2 %, Figure 2.3B; Supplemental 
Table S2.3), a result which we have previously demonstrated (McVicker et al., 2014). 
Conversely, we observed a significant decrease (p < 0.05) in the number of static events 
for Y18E 3RS-Tau (47.7 ± 5.0 %, Figure 2.3B; Supplemental Table S2.3). 
Static dwell times for WT 3RS-Tau were best fit to a two phase exponential function. 
This revealed one population of long dwell times and one of short dwell times 
(Supplemental Figures S2.2A and S2.3; Supplemental Table S2.3), most likely 
corresponding to the small multi-protein complexes (long dwell times) and single 
molecule interactions (short dwell times) with the microtubule surface that we have 
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previously observed in the static state (McVicker et al., 2014). Y18E 3RS-Tau static 
dwell times were best fit to a one phase exponential function (Supplemental Figure S2.2B 
and S2.3; Supplemental Table S2.3) with an average of 14.5 s which is comparable to 
WT 3RS-Tau’s long static dwell time of 15.7 s. Dynamic dwell times for both WT and 
Y18E 3RS-Tau were best fit to one phase exponential functions (Supplemental Figure 
S2.2C and D; Supplemental Figure S2.3; Supplemental Table S2.3) and did not differ 
from each other. The ability to control the equilibrium between the static and dynamic 
states of Tau, and to specifically regulate that control by mimicking phosphorylation at 
Y18, has not been previously demonstrated. 
Phospho-mimetic constructs of Y18 3RS-Tau bind with decreased affinity for the 
microtubule. Given the observed shift towards the dynamic state we considered the 
possibility that the introduction of negative charge at Y18 reduced Tau’s affinity for the 
microtubule surface. This would also lead to a decrease in 3RS-Tau’s ability to inhibit 
kinesin-1 motility. To address this, TIRF microscopy was used to image increasing 
concentrations (50-650 nM) of Alexa 532 labeled 3RS-Tau binding to HiLyte 488 
labeled, paclitaxel stabilized microtubules (Figure 2.4A). An unphosphorylatable 
construct (Y18A 3RS-Tau) and a construct with increased negative charge (dE 3RS-Tau) 
were observed alongside WT and Y18E 3RS-Tau in an effort to better understand the 
effect of the introduction of negative charge. The average intensity of Alexa 532 labeled 
3RS-Tau per unit length along the microtubule was measured and plotted against Tau 
concentration. The plots were then fit to one site-specific binding curves from which the 
KD was determined. We found that WT 3RS-Tau binds the microtubule with a KD of 150 
± 126 nM while Y18A 3RS-Tau had a KD of 331 ± 100 nM (Figure 2.4B; Supplemental 
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Table S2.3). Introduction of increasing negative charge decreased the affinity of Tau for 
the microtubule as evidenced by a KD of 700 ± 318 nM for Y18E 3RS-Tau with an even 
greater decrease for dE 3RS-Tau (  of 902 ± 266 nM) (Figure 2.4B; Supplemental 
Table S3). 
Phospho-mimetic mediated shift towards the dynamic state is maintained for comparable 
bound fractions of 3RS-Tau. Using the KD values from our binding assays, we determined 
that at a microtubule concentration of 1 uM, WT 3RS-Tau had a bound fraction of 87% 
while Y18E 3RS-Tau’s bound fraction was 59%. At the high concentration used in our 
kinesin-1 motility assays (200 nM; 1:5 (Tau:tubulin)), WT 3RS-Tau would have a 
microtubule bound concentration of 174 nM while Y18E 3RS-Tau would have 118 nM 
bound. The inhibition of kinesin-1 by Y18E 3RS-Tau that we observed for this high 
concentration could then be attributed to this difference in bound fraction of Tau. To 
address this possibility, we observed WT, control (Y18A) and phospho-mimetic (Y18E, 
dE) constructs of 3RS-Tau at 10 nM (1:3000; Tau:tubulin) where the bound 
concentrations of WT (9 nM), Y18A (7 nM), Y18E (7 nM) and dE (5 nM) 3RS-Tau were 
comparable. At this concentration, the percentage of static events for Y18A (77.8 ± 
4.2%) was not significantly different from WT 3RS-Tau (81.4 ± 3.9%) (Figure 2.5; 
Supplemental Table S2.3). Under these conditions Y18E 3RS-Tau had a static population 
of 67.4 ± 4.7% (Figure 2.5; Supplemental Table S2.3) which was a statistically 
significant difference from WT 3RS-Tau (p < 0.05) and Y18A 3RS-Tau (p < 0.05) 
(Figure 2.5; Supplemental Table S2.3). dE 3RS-Tau had a static population of 51.4 ± 
5.0% (Figure 2.5; Supplemental Table S2.3) which was a statistically significant decrease 
compared to Y18E 3RS-Tau (p < 0.05).   
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Dynamic state dwell times for WT, Y18A, Y18E and dE 3RS-Tau (Supplemental Figure 
S2.4, A-D; Supplemental Table S2.3), were best fit to one phase exponential functions 
and did not significantly differ. Dwell times for static events from WT, Y18A, Y18E and 
dE 3RS-Tau populations were best fit to two phase exponential functions (Supplemental 
Figure S2.5, A-D). Though there was a slight decrease in the long and short dwell times 
for Y18E 3RS-Tau (Supplemental Figure S2.5C; Supplemental Table S2.3) and an 
increase in the short dwell time for dE 3RS-Tau (Supplemental Figure S2.5D; 
Supplemental Table S2.3); the WT, Y18A and dE 3RS-Tau dwell times (long) were not 
appreciably different. This result indicates that the observed shift towards the dynamic 
state is independent of the fraction of Tau bound to the microtubule. 
Negative charge mediated shift towards the dynamic state is maintained ex vivo. All the 
in vitro assays presented here were performed at low ionic strength. We therefore asked if 
the effect of negative charge on 3RS-Tau’s behavior was still present under more 
physiologically relevant conditions. TIRF microscopy was used to visualize Tau behavior 
(Figure 2.6) in ex vivo preparations of axoplasm extruded from the giant axons of 
Atlantic squid (Loligo pealei). The extruded axoplasm samples were perfused with a 
mixture of Alexa 568 labeled WT, Y18A or Y18E 3RS-Tau to visualize microtubules and 
Alexa 488 labeled WT, Y18A or Y18E 3RS-Tau to observe single molecule events 
(Supplemental Movie S2.4 and S2.5). Non-phosphorylatable Y18A 3RS-Tau had a static 
population of 82.0 ± 3.8 % (Figure 2.7; Supplemental Table S2.3). This was statistically 
significant from static populations for WT (74.0 ± 4.4 %) and Y18E 3RS-Tau (73.2 ± 4.4 
%) (p < 0.05) (Figure 2.7; Supplemental Table S2.3). These results highlight the 
importance of using an unphosphorylatable construct to prevent possible ex vivo 
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phosphorylation at Y18. Based on this data we conclude that the Y18E mediated shift 
towards the dynamic state observed in vitro is maintained within the axoplasm. Unlike 
the in vitro dwell times, all ex vivo dwell times for WT, Y18A and Y18E 3RS-Tau best 
fit a single exponential function. There was no difference in the ex vivo static dwell times 
(Supplemental Figure S2.6, A-F; Supplemental Table S2.3) for WT, Y18A and Y18E 
3RS-Tau. We observed ex vivo dwell times which were an order of magnitude shorter 
than the in vitro dwell times (Supplemental Figures S2.2, S2.4 and S2.5). This difference 
has been previously observed (Janning et al., 2014) and can most likely be attributed to 
the increased ionic strength found under physiological conditions. This is the first 
evidence demonstrating that the static-dynamic equilibrium of Tau on the microtubule 
surface observed in vitro is present under conditions found within the axon. 
2.4 Discussion 
Recently, we have shown that Tau’s established ability to inhibit kinesin-1 
motility differs with isoform (McVicker et al., 2014). However, the cellular means of 
regulating Tau’s inhibition of kinesin-1 is still not understood. Y18 phosphorylation is of 
particular interest because of its role in preventing the inhibition of axonal transport in the 
disease state (Kanaan et al., 2012) and its possible involvement in stabilizing a non-
disease state dynamic folded conformation of Tau in solution (Jeganathan et al., 2006). 
Our results (Figure 2.2) are the first evidence of phosphorylation regulating Tau’s ability 
to inhibit kinesin-1.  
We hypothesized two possible explanations for the reduced inhibition of kinesin-
1. Introduction of negative charge at Y18 could shift the static-dynamic state equilibrium 
towards the less inhibitory dynamic state. Alternatively, the negative charge at Y18 could 
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decrease Tau’s affinity for the microtubule surface, effectively reducing the number of 
Tau obstacles for kinesin-1 to circumnavigate. Specifically for our kinesin-1 motility 
assay conditions (1:5, Tau:tubulin) (Figure 2.2), a final concentration of 200 nM Tau was 
used for which WT 3RS-Tau had a fraction bound of 87% (174 nM) compared to Y18E 
3RS-Tau’s fraction bound of 59% (118 nM) (based on binding assay results; Figure 2.4). 
But we also found that Y18E 3RS-Tau’s shift towards the dynamic state is maintained at 
comparable fractions of Tau bound to the microtubule surface (5-9 nM) (Figure 2.5). 
Therefore, the dynamic state shift observed upon Y18 phosphorylation is intrinsic to 
behavior of individual Tau molecules and not dependent on amount of Tau bound to the 
microtubule.  
However, the difference in affinity for the microtubule between WT and Y18E 
3RS-Tau must still be taken into account. Though the exact structural changes that 
underlie static vs dynamic binding are not well understood, the negative charge mediated 
decrease in affinity indicates that long range structural interactions may affect protein 
binding and behavior. Based on the behavior observed in the high concentration 
dynamics assays (Figure 2.3), 134 nM of the bound WT 3RS-Tau would be static while 
for Y18E 3RS-Tau 56 nM would be static. For 1 µM of microtubules, statically bound 
WT 3RS-Tau would occupy 13% of the available kinesin-1 binding sites while static 
Y18E 3RS-Tau would occupy 5% of the available binding sites. This indicates that Y18E 
3RS-Tau’s decreased inhibition of kinesin-1 is due to a combination of a decreased 
bound fraction and an equilibrium shift towards the dynamic state. Ultimately this leads 
to a reduction in the number of static Tau obstacles that kinesin-1 encounters on the 
microtubule surface. 
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It has previously been demonstrated that with increasing concentration Tau forms 
multi-protein patches on the microtubule surface (Dixit et al., 2008). Our high 
concentration behavioral assays (Figure 2.3, Supplemental Table S2.3) show two 
populations of WT 3RS-Tau static dwell times. The long dwell time (Supplemental Table 
S2.3, Supplemental Figures S2.2 and S2.3) may be indicative of multi-protein complexes 
formed by N-terminal region mediated Tau-Tau interactions (Feinstein et al., 2016). The 
loss of a short static dwell time for Y18E 3RS-Tau (Supplemental Table S2.3, 
Supplemental Figure S2.2) indicates that with the introduction of negative charge at high 
concentration, static binding may only occur when multi-protein complexes are formed. 
Additionally, the introduction of N-terminal negative charge may disrupt complex 
formation (Feinstein et al., 2016) which would lead to the observed shift towards 
dynamic binding at high concentration (Supplemental Table S2.3). In keeping with these 
results we have previously shown that 4RL-Tau which has two acidic N-terminal inserts, 
forms smaller multi-protein complexes and is more shifted towards dynamic binding than 
3RS-Tau which has no acidic inserts (McVicker et al., 2014). At low concentration 
(Figure 2.3), static binding is not governed by concentration driven complex formation.  
Tau’s inhibition of kinesin-1 motility does not impact velocity (Supplemental 
Table S2.2) (Dixit et al., 2008). We have previously demonstrated that while kinesin-1 
pauses both in the presence and absence of Tau the pause-step frequency does not change 
(Hoeprich et al., 2014). Therefore, the effect of pausing on velocity is not significant. An 
increase in run termination would lead to the observed decrease in run length.  
We have previously reported the importance of the lattice structure in regulation 
of Tau isoforms’ static-dynamic state equilibria (McVicker et al., 2014). Tau’s ability to 
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inhibit kinesin-1 motility is also regulated by lattice structure (McVicker et al., 2011). On 
GMPCPP stabilized microtubules, 3RS-Tau binds dynamically and does not inhibit 
kinesin-1 motility (McVicker et al., 2011; McVicker et al., 2014). Tau’s inhibitory effect 
is restored on paclitaxel stabilized microtubules where 3RS-Tau’s binding equilibrium is 
shifted towards the static state (McVicker et al., 2011; McVicker et al., 2014). The 
present study demonstrates that lattice regulation is not the only means available for 
control of Tau’s binding equilibrium. Controlling Tau’s intrinsic equilibrium through 
phosphorylation and the microtubule lattice structure through nucleotide binding states 
and PTMs (McVicker et al., 2014; Yu et al., 2015) gives the cell greater flexibility in 
regulating Tau obstacles and allows for continued AT. We have demonstrated that Tau’s 
static-dynamic state equilibrium is maintained under physiological conditions and that the 
shift towards the dynamic state that we observed in vitro occurs ex vivo (Figure 2.5). As 
we have shown and has been previously reported (Janning et al., 2014), Tau binds both 
dynamically and transiently to the microtubule surface under physiological conditions. 
Extending this observation, we emphasize the importance of regulating these dynamic 
interactions to control Tau function. It should be noted that the dwell times reported here 
are longer than those previously reported (Janning et al., 2014), which may relate to the 
different Tau constructs and neuronal systems used, and highlight the importance of 
further study to better understand Tau dynamics in vivo.  
Within the axon phosphorylation of Y18, the last residue of the PAD, not only 
shields the PAD (Kanaan et al., 2012), but as our results show, the negative charge 
provided by phosphorylation facilitates a dynamic state shift independent of fraction 
bound (Figures 2.3 and 2.5). This gives the cell two levels of regulating Tau’s function by 
63 
preventing Tau signaling through the PAD and Tau’s physical inhibition of kinesin-1 
motility. In this model while Y18 is phosphorylated, individual motors continue to 
transport cargo (Figure 2.8). Dephosphorylation of Y18 leads to signaling activation 
(Kanaan et al., 2012) and increased physical inhibition of kinesin-1 motility (Figure 2.8). 
Exposure of Tau’s PAD has been shown to ultimately activate glycogen synthase kinase 
3β (GSK-3β) which in addition to phosphorylating Tau (Lovestone et al., 1996; Martin et 
al., 2013b) can phosphorylate kinesin light chains (Morfini et al., 2002) (Figure 2.8). 
This leads to further disruption of cargo-motor interactions leading to the dissociation of 
motors from cargo, thereby allowing cargo delivery (Morfini et al., 2002) (Figure 2.8).   
PAD shielding by phosphorylation of Y18 (Kanaan et al., 2012) may partly 
depend on structural change. The misregulation of Tau’s structure (Elbaum-Garfinkle and 
Rhoades, 2012) and therefore its function could be a common pathway by which 
neurodegeneration occurs in diseases where shifts in isoform expression and aberrant 
phosphorylation lead to the same outcome (Qian et al., 2013; Gerson et al., 2014).  
Control of Tau’s function is further complicated by abnormal modifications which 
occur in the disease state (Morris et al., 2015). Our group and others have previously 
shown that Tau’s ability to inhibit kinesin-1 motility differs with isoform (Vershinin et 
al., 2007; Dixit et al., 2008; McVicker et al., 2011) as does the static-dynamic state 
equilibrium (McVicker et al., 2014). The results we present here indicate that 
phosphorylation provides a common means of regulating the isoforms and their 
equilibria. Perturbing the equilibrium between the static and dynamic states would lead to 
disruption of cargo transport within the axon by disrupting inhibition of kinesin-1 
motility and release of cargo. Given our results, it is highly likely that the equilibrium 
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between the static and dynamic states is spatially regulated in order to effectively control 
local cargo delivery. This localized signaling would require the involvement of multiple 
signaling pathways and a complex pattern of Tau phosphorylation. To date, it is not 
known how these phosphorylation events affect the normal behavior of the protein or 
how the cell balances N- and C-terminal phosphorylation to maintain a working static-
dynamic state equilibrium. In addition to phosphorylation, Tau is subject to acetylation 
(Kamah et al., 2014) and methylation (Funk et al., 2014), whose purposes in the 
regulation of Tau’s function have yet to be fully understood. It is imperative that the 
balance of non-disease state modifications, especially phosphorylation, is understood 
given that one of the first steps in neurodegeneration may be disruption of these normal 
modifications. We have begun to elucidate the importance of regulating phosphorylation 
at specific sites to control Tau function. Here we have highlighted new implications for 
the cellular control of Tau’s static-dynamic state equilibrium in axonal transport under 
both normal and disease state conditions. 
2.5 Materials and Methods 
All protein work and experiments were done in BRB80 (80 mM PIPES, 1 mM 
EGTA, 1 mM MgCl2, pH 6.9 at room temperature) unless otherwise noted. 
Tau Mutant Generation, Purification and Labeling Alanine/glutamic acid 3RS-Tau 
constructs were generated using the QuikChange II XL Site-Directed Mutagenesis Kit 
(Agilent Technologies, Santa Clara, CA). Constructs were then expressed in BL21-
CodonPlus(DE3)-RP Escherichia coli cells (Stratagene, La Jolla, CA) and purified using 
Q and SP Sepharose (Sigma-Aldrich, St. Lois, MO) affinity column chromatography 
(McVicker et al., 2011; McVicker et al., 2014).  Following purification, samples were 
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dialyzed against BRB80 and protein concentrations were determined with the bicinchonic 
acid (BCA) assay (Pierce, Rockford, IL) using WT 3RS-Tau standards. The 
concentrations were then validated with SDS PAGE gels (Bio-Rad, Hercules, CA). For 
labeling, samples were incubated with 10-fold molar excess Dithiothreitol (DTT) at room 
temperature for 2 h followed by DTT removal with a 2 ml 7K MWCO ZebaTM spin 
desalting column (Peirce, Rockford, IL). Samples were then incubated with 3-fold molar 
excess of Alexa Fluor® (488, 532 or 568) C5 Maleimide (Invitrogen Molecular Probes, 
Carlsbad, CA) for 2 h at room temperature. Excess fluor was removed with desalting 
columns. A 640® Spectrophotometer (Beckman, Pasadena, CA) was used to determine 
the labeling efficiency using the following Alexa extinction coefficients: Alexa 488 – 
71,000 cm-1M-1 at 495 nm; Alexa 532 – 78,000 cm-1M-1 at 532 nm; Alexa 568 – 88,000 
cm-1M-1 at 578 nm. The protein concentration was determined using the BCA assay and 
the ratio of fluor concentration to protein concentration was calculated. All Tau proteins 
had labeling efficiencies of 30 - 86% (detailed in Supplemental Table S2.1). 
Tubulin Purification and Microtubule Preparation Tubulin was purified from bovine 
brain obtained from Vermont Livestock & Slaughter (Ferrisburgh, VT) as previously 
described (McVicker et al., 2014). Purified tubulin was clarified by ultracentrifugation 
(20 min, 95,000 rpm, 4oC) in an OptimaTM TLX Ultracentrifuge (Beckman, Pasadena, 
CA). Following clarification, tubulin was mixed with rhodamine-labeled tubulin 
(Cytoskeleton Inc., Denver, CO) at a 1:200 (labeled:unlabeled) ratio  and supplemented 
with 1 mM GTP (Sigma-Aldrich, St. Lois, MO). This mixture was incubated for 20 min 
at 37oC. Following polymerization, microtubules were stabilized with 20 µM paclitaxel 
(Sigma-Aldrich, St. Lois, MO). Post-clarification tubulin concentration was calculated 
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with the spectrophotometer using the tubulin extinction coefficient of 115,000 cm-1M-1 at 
280 nm.  
Coverslip Preparation and Flow Chamber Assembly For silanization, glass coverslips 
were incubated in 100% methanol for 2 h with shaking. Methanol-washed coverslips 
were then plasma cleaned (Harrick Plasma Cleaner, HarrickPlasma, Ithaca, NY) for 2-5 
min and then incubated in a silane mixture (97% toluene (Sigma-Aldrich, St. Lois, MO), 
2% 2-methoxy(polyethyleneoxy)propyltrimethoxysilane (Gelest Inc., Morrisville, PA), 
and 1% butylamine (Acros Organics, New Jersey, USA)) with flowing nitrogen gas for 
90 min (Lowndes and Nelson, 2013). Coverslips were then washed in toluene (Lowndes 
and Nelson, 2013) and then dried and cured with flowing nitrogen gas for 30 min. Using 
Norland optical adhesive (Norland Products, Cranbury, NJ), flow chambers were 
constructed by adhering ARTUS shims (ARTUS, Eaglewood, NJ) to the silanized glass 
coverslips before 15 min UV irradiation (McVicker et al., 2011).  
In vitro TIRF Dynamics Assay Paclitaxel stabilized microtubules were incubated with 
WT, alanine (Y18A), single glutamic acid (Y18E) or double glutamic acid (dE) 3RS-Tau 
constructs at a 1:3000 (Tau:tubulin) ratio (10-12 nM) 30 min prior to imaging. For 
imaging, washes and incubations were performed with BRB80+OS (BRB80 
supplemented with a previously published oxygen scavenging system (McVicker et al., 
2011)). Flow chambers were incubated with monoclonal anti-β III (neuronal) tubulin 
antibodies (Sigma-Aldrich, St. Lois, MO) at 33 µg/mL for 5 min followed by a 5 min 2X 
chamber volume wash with 2mg/mL BSA (Sigma-Aldrich, St. Lois, MO). Alternatively, 
a 5 min 2.5% Pluronic® F-127 (Sigma-Aldrich, St. Lois, MO) incubation was done before 
the chambers were washed (10X chamber volume) with BSA for 5 min to remove excess 
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Pluronic® F-127. Chambers were then incubated for 12 min with microtubule/Tau 
mixtures diluted to 0.5-1 µM. Finally, chambers were washed with 160-333 pM Tau 
(1:3000 imaging concentration) for 2-4 min to remove non-adherent microtubules. All 
Tau and microtubule dilutions were made in warm (37oC) BRB80+OS. 
To observe Tau’s behavior at a 1:5 (Tau:tubulin) ratio, the needed concentration 
of unlabeled WT or Y18E 3RS-Tau (200 nM) was spiked with 500 pM Alexa 488 labeled 
WT or Y18E 3RS-Tau. Microtubules were stabilized as described above and were 
incubated with either the WT or Y18E 3RS-Tau spike mixture 30 mins prior to imaging. 
As before, washes and incubations were performed with warm BRB80+OS. 
Microtubule/Tau mixtures were diluted to a final imaging concentration of 1 µM. 
Chambers were prepared as previously detailed and were then incubated with diluted 
microtubule/Tau mixtures. Chambers were washed with warm WT or Y18E 3RS-Tau 
mixtures (see above for concentrations) to remove non-adherent microtubules and keep 
Tau concentrations constant (2-4 min).  
An inverted Eclipse Ti-U Microscope (Nikon, Melville, NY) with a 100X 
PlanApo objective lens (1.49 NA) and auxiliary 1.5X magnification and an XR/Turbo-Z 
(Stanford Photonics, Palo Alto, CA) camera running Piper Control v2.3.39 or v2.6.09 
(Stanford Photonics, Palo Alto, CA) was used to perform TIRF microscopy as previously 
described (Previs et al., 2012; Hoeprich et al., 2014; Previs et al., 2015). Alexa 488 
labeled Tau and rhodamine labeled tubulin were excited and imaged as previously 
described with 473 nm or 532 nm argon lasers and previously reported emission filters 
(McVicker et al., 2014). Images were collected at room temperature at 10 frames/s, 95 or 
93 nm/pixel, 50 frames for microtubules and 500 or 1000 frames for Tau.  
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TIRF Binding Assay The affinity and cooperativity of 3RS-Tau binding to microtubules 
were assessed using a TIRF-based binding assay. Microtubules were prepared as 
described above expect that labeling was carried out with porcine HiLyte 488 labeled 
tubulin (Cytoskeleton Inc., Denver, CO) at a 1:400 (labeled:unlabeled) ratio. Tau 
constructs were labeled with Alexa 532 as described above. As with the in vitro 
Dynamics Assay, all dilutions, washes and incubations were done in BRB80+OS. Final 
Tau and microtubule dilutions were done in warm BRB80+OS as described above. 
Microtubules were polymerized as described except that no Tau was added prior to 
imaging. Microtubules were then flowed into prepared flow chambers at 1.5 µM as 
described above. Initially, chambers were washed to remove non-adherent microtubules. 
Then, 50 nM Tau was flowed in and imaged.  Following this, increasing concentrations 
of Tau were flowed in and imaged until a final concentration of 650 nM was reached. 20 
frames of Tau were collected at 10 frames/s for each concentration. Imaging was done on 
the same system with the same conditions used for the in vitro TIRF Dynamics Assay 
described above.  
Ex vivo TIRF Dynamics Assay To visualize Tau under physiological conditions, 
Atlantic squid (Loligo pealii; Marine Biological Laboratory in Woods Hole, MA) axons 
were isolated and their axoplasms extruded following previously established protocols 
(Brady et al., 1993; Song and Brady, 2013). Briefly, flow chambers were constructed 
using 25 x 75 x 1 mm glass slides (VWR Scientific, Radnor, PA) and strips of 22  22 
mm coverslips (VWR Scientific, Radnor, PA) cut with a diamond tipped pen and coated 
with Compound III Silicon grease (Dow Corning, Midland, MI). Paired axoplasms were 
extruded onto individual chamber slides. Flow chambers were then completed by adding 
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a top coverslip that was silanized as previously described. Chambers were then secured 
with a 1:1:1 lanoline, vaseline and paraffin mixture (Song and Brady, 2013).  
Tau constructs were initially diluted in 20 mM HEPES (pH 7.2) and all axoplasm 
imaging was done in Buffer X/0.8 (437.5 mM potassium aspartate, 162.5 mM taurine, 
87.5 mM betaine, 62.5 mM glycine, 25 mM HEPES, 16.25 mM MgCl2, 12.5 mM EGTA, 
3.75 mM CaCl2, 1.25 mM glucose, pH 7) (Song and Brady, 2013) diluted to Buffer X/2 
with ddH2O. Perfusion mixtures were made with 200 nM Alexa 568 labeled Y18A or 
Y18E 3RS-Tau, 500 pM Alexa 488 labeled Y18A or Y18E 3RS-Tau and a final ATP 
concentration of 1 mM. Following perfusion, axoplasms were incubated at room temp for 
20 min before imaging began. An inverted Eclipse Ti microscope (Nikon, Melville, NY) 
with a 100x Apochromatic objective lens (1.49 NA) was used to carry out TIRF 
microscopy with 488 nm (LU-NV laser combiner, Nikon, Melville, NY) and 561 nm 
(Agilent MLC400 Monolithic Laser Combiner, Santa Clara, CA) lasers and emission 
band-pass filter sets 525/50 nm and 600/50 nm (Chroma Technology, Bellows Falls, VT). 
An Andor iXon Ultra 897 camera (Belfast BT12 7AL, UK) running NIS-Elements AR 
v4.30.02 (Nikon, Melville, NY) was used to image Tau in the axoplasm. The relatively 
high concentration of Alexa 568 (200 nM) labeled Tau allowed for visualization of 
microtubules while the low Alexa 488 (500 pM) labeled Tau concentration allowed 
imaging of single Tau molecules. One hundred frames each were collected at room 
temperature of microtubules and Tau with an interval of 0.3 s and a pixel size of 0.16 x 
0.16 µm. 
In vitro Kinesin-1 Motility Assay Motility assays were performed with a truncated (560 
aa) Drosophila melanogaster biotin tagged kinesin-1 construct (gift from Hancock lab). 
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Motors were labeled with streptavidin conjugated Qdot® 655 (Life Technologies, 
Carlsbad, CA) at a 1:4 (motor:Qdot) ratio. Paclitaxel stabilized microtubules were 
prepared as described above except that after polymerization microtubules were 
centrifuged at room temperature for 30 min before the pellet was resuspended in motility 
assay buffer (MAB) (10 mM PIPES, pH 7.4 at room temperature, 50 mM potassium 
acetate, 4 mM magnesium acetate, 1 mM EGTA) at 37oC supplemented with an oxygen 
scavenging system (MAB+OS) as previously described (Hoeprich et al., 2014). Prior to 
imaging, microtubules were incubated with Tau (Alexa 488 labeled or unlabeled WT or 
Y18E 3RS-Tau) at a 1:5 (Tau:tubulin) ratio for 20 min at 37oC. Flow chambers were 
prepared by incubation with monoclonal anti-tubulin antibodies (detailed above) diluted 
with MAB+OS. Blocking and washing were done as previously detailed. Briefly, 
chambers were blocked with 0.5 mg/mL of BSA in MAB+OS before 1 μM of 
microtubules or microtubules/Tau as added and incubated as for the Tau behavioral 
assays. Non-adherent microtubules were removed with an MAB+OS wash. A working 
concentration of 20 pM – 50 pM kinesin-1 along with 1 mM ATP was added just prior to 
imaging. Imaging was performed on the same system as the in vitro Tau assays. Qdots 
were excited with the 473 nm laser and all movies were acquired at five frames per 
second.  
Data Analysis In vitro TIRF Dynamics Assays ImageJ 1.48v (NIH, Bethesda, MD) was 
used to create kymographs of Tau interacting with the microtubule using the 
MultipleKymograph plugin. To determine dwell times, the MTrackJ plugin was used to 
measure the length of events that were clearly static or dynamic. Eleven percent of events 
display switching and were not included in further analysis. Only events that began, 
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remained and ended on the microtubule during the imaging period were used. Dynamic 
and static dwell times were exported to GraphPad Prism v6.00 (GraphPad Software, La 
Jolla, CA). Cumulative frequency distribution plots were generated for each population 
and fit to one or two phase exponential functions. Average dwell times were calculated as 
the time constant of the exponential function. The goodness of the fit (R2) and the 95% 
confidence bands were also reported.  Fisher’s Exact Test was used to determine 
statistical significance for static compared to dynamic populations of 3RS-Tau construct 
data sets. All data sets are composites of data collected on different days. High 
concentration (Spike): (WT, N = 8; Y18E, N = 8), comparable bound fraction: (WT, N = 
12; Y18A, N= 5; Y18E, N = 4; dE, N = 5). 
Ex vivo TIRF Dynamics Assay Events were tracked using the MTrackJ plugin for ImageJ. 
Events were chosen if they lasted more than one frame and if the signal remained within 
a snap range of 13 x 13 pixels from one frame to the next (snap range chosen based on 
maximum diffusive range of a Tau protein (Konzack et al., 2007)).  Tracks were exported 
to Excel and events with a max distance from start  0.5 µm were designated static while 
events  0.5 µm were designated dynamic. GraphPad Prism was used as described 
above, to plot the cumulative frequency distribution of the dwell times to which one 
phase exponential functions were fit. The average dwell time was determined from the fit 
of the exponential function. As above, the goodness of the fit (R2) and the 95% 
confidence bands were reported. Statistical significance was determined using Chi-square 
with Yates’ correction. All data sets are comprised of data collected on different days 
(WT, N = 4; Y18A, N= 5; Y18E, N = 5). 
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TIRF Binding Assay The average intensity (Avg I; Arbitrary Units) per unit length of Tau 
binding the microtubule was measured for each frame using the Multi Measure plugin for 
ImageJ. In GraphPad Prism, the average AvgI per unit length was used to plot 
 vs [Tau]. Binding curves were fit to one site-specific binding with Hill 
slope, which was used to determine the Hill coefficient and KD using the Hill equation: 
 
where h is the Hill coefficient and Amax is the maximum  The  
reported here was normalized to Amax. Tau’s fraction bound (fB) for the kinesin-1 
motility assay was determined using the equation: 
 
where [MT] is the concentration of microtubules used for imaging and  is the 
affinity of Tau for the microtubule surface calculated in the binding assay. All data sets 
are comprised of data collected on different days (WT, N = 4; Y18A, N= 3; Y18E, N = 
3). 
In vitro Kinesin-1 Motility Assay Data were analyzed as reported previously (Hoeprich et 
al., 2014). Briefly, the MTrackJ plugin for ImageJ was used to measure motility while the 
segmented line tool was used to measure track lengths. Average velocity was plotted as a 
histogram and fit to a Gaussian distribution. The mean and standard deviation are 
reported here. Using methods that we have previously outlined (Thompson et al., 2013), 
cumulative frequency plots were generated for run lengths corrected for microtubule 
track length effects (through resampling of the data) and reported here (99% confidence 
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level of data resampling repeated 10,000 times). Statistical significance was determined 
as previously described (Thompson et al., 2013). All data sets are comprised of data 
collected on different days (No Tau, N = 10; WT, N = 10; Y18E, N = 10). 
Statistics For the motor motility assay average velocities for events were fit to a Gaussian 
distribution. The mean of the average velocities and standard deviation of those velocities 
are reported here. It has been shown that motor run length is affected by the length of the 
track (Thompson et al., 2013). Differences in microtubule track length that might lead to 
underestimation of motor run length were corrected using previously published work 
(Thompson et al., 2013). Average run lengths were determined using a bootstrapping 
method where data was resampled with replacement (for the size of the data set) 10,000 
times (Thompson et al., 2013).  The standard deviation in these values is reported. 
Statistical significance was determined as previously described by comparing resampled 
data for the run length (difference between observed and control run lengths) to a null 
hypothesis (Thompson et al., 2013).  
For the in vitro and dynamics assays, the percentage of events that were static or 
diffusive are reported for 14 experiments. The error bars represent the standard deviation 
in the percentage of static or diffusive events across 14 separate experiments. 
Significance was determined using Fisher’s Exact Test (a variation of a Chi-squared test 
which calculates an exact P-value) best used when the sample size is small. 
 Like the in vitro dynamics assays, the ex vivo dynamics assay reports the 
percentage of static or diffusive events for a dataset made up of 5 experiments. The error 
bars are also the standard deviation in the percentage of static or diffusive events across 5 
experiments. Because of the larger sample size, significance was determined using a Chi-
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squared test with Yates’ correction to improve the P-value approximation of the Chi-
squared test. 
 The TIRF binding assay reports the average intensity per unit length at each 
concentration imaged. The error bars represent the standard deviation in intensity at each 
concentration over 4 experiments.  
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Figure 2. 1 Representative kymographs of kinesin-1 motility. 
TIRF microscopy was used to observe kinesin-1 motility was in the absence of Tau 
and in the presence of unlabeled or Alexa 488 labeled WT and Y18E 3RS-Tau 
(200 nM (1:5, Tau:tubulin)). Continuous (A), Run-Pause-Run (B) and Pause-
Terminate (C) events were observed under all conditions. 
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Figure 2.2 Diagram of motility assays with cumulative frequency plots of run 
lengths (mean ± SD) for kinesin-1 in the absence and presence of 3RS-Tau.  
A) Flow chambers were passivated with PEG-silane (blue) before tubulin antibodies 
(black) were used to adhere paclitaxel stabilized microtubules (green). Q-dot labeled 
kinesin-1 (purple/red) motility was observed on undecorated or label/unlabeled Tau 
(yellow) decorated microtubules. Inset: Unlabeled microtubules coated with 200 nM 
Alexa 488 labeled Tau. B) On undecorated microtubules, kinesin-1 had a run length of 
1.64 ± 0.50 m. Introduction of both unlabeled (C) and labeled (D) WT 3RS-Tau, 
significantly reduced kinesin-1’s run length to 0.99 ± 0.23 and 0.99 ± 0.24  m (p < 
0.05). In the presence of unlabeled (E) and labeled (F) Y18E 3RS-Tau, kinesin-1’s run 
length was significantly increased to 1.37 ± 0.39 m (p < 0.05) and 1.35 ± 0.40 m (p 
< 0.05), respectively. Introduction of negative charge reduced Tau’s ability to inhibit 
kinesin-1 motility and led to a significant increase in run length (Supplemental Table 
S2.2). Experiments: 10. 
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Figure 2.3 Comparison of WT and Y18E 3RS-Tau behavior on Taxol stabilized 
microtubules at high concentration.  
A) Representative kymographs show the different types of behaviors that can be 
observed. Tau can bind statically (Static: horizontal lines) while interacting with the 
microtubule or exhibit dynamic binding along the microtubule surface (Dynamic: 
jagged lines). Tau can also switch between these states (Switch). B) Bar graph 
comparing the percentage (± SD) of static to dynamic events for WT and Y18E 3RS-
Tau. For WT 3RS-Tau, 77.1 ± 4.2% of events were static while Y18E 3RS-Tau’s 
equilibrium was shifted towards the dynamic state (47.7 ± 5.0% static events). (**** 
denotes a statistically significant difference of p < 0.05). Events: WT = 388, Y18E = 
235 from eight experiments. 
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Figure 2.4 Comparison of TIRF binding assays.  
TIRF binding assays for WT (N = 4), Y18A (N = 3), Y18E (N = 3) and dE (N 
= 3) 3RS-Tau. WT 3RS-Tau had a KD (mean ± SD) of 150 ± 126 nM, Y18A 
3RS-Tau had a KD of 331 ± 100 nM, Y18E 3RS-Tau had a KD of 700 ± 318 nM 
and dE 3RS-Tau had a KD of 902 ± 266 nM. The affinity of Tau for the 
microtubule surface decreases with the introduction of increasing negative 
charge at Y18. 
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Figure 2.5 The behavior of comparable bound fractions of WT, Y18A, 
Y18E and dE 3RS-Tau on paclitaxel-stabilized microtubules.  
A) Representative kymographs show both dynamic (jagged line) and static 
binding along the microtubule surface (horizontal lines). B) Bar graph 
comparing the percentage of static to dynamic events (percentage ± SD) for each 
Tau construct. Introduction of negative charges at Y18 and T17 shifted the 
equilibrium between the static and dynamic states towards the dynamic state. 
(****) denotes a statistically significant difference of p < 0.05. Events: WT = 
566 (N = 12), Y18A = 320 (N = 5), Y18E = 472 (N = 4), and dE = 220 (N = 5). 
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Figure 2.6 Static and dynamic (arrow) binding events with the axoplasm.  
Squid giant axon axoplasm samples were used to image WT, Y18A and Y18E 3RS-
Tau interactions (500 pM Alexa 488 labeled Tau, green) with axonal microtubules 
(200 nM Alexa 568 labeled Tau, red). Tau binds both statically and dynamically under 
physiological conditions. 
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Figure 2.7 Tau’s binding equilibrium between static and 
dynamic states is maintained ex vivo.  
Bar graph comparing the percentage (± SD) of static to dynamic 
events for Y18E and Y18A 3RS-Tau in the axoplasm 
preparation. As observed in vitro (Figures 3 and 5), a shift in 
Tau’s equilibrium towards the dynamic state was observed upon 
introduction of negative charge at Y18. ****:p < 0.05. Events: 
Y18A = 972 (N = 5), WT =1129 (N = 4), Y18E = 757 (N = 5). 
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Figure 2.8 Model of Tau regulation. 
Results from our work here indicate that Y18 phosphorylation (yellow) not only 
prevents PP1 activation induced by exposed PAD (light blue) (Kanaan et al., 2012), 
but also stabilizes Tau (blue) in the dynamic state, allowing for continued kinesin-1 
(red) mediated cargo transport. On the other hand, Y18 dephosphorylation would 
shift Tau’s equilibrium towards the more inhibitory static state while allowing PAD 
activation of PP1 (pink) upon exposure. PP1 would then dephosphorylate and activate 
GSK-3β (orange), which in turn phosphorylates kinesin-1 light chains and promotes 
dissociation from its transported cargoes. Thus, misregulation of Tau’s dynamic 
equilibrium could promote neuronal degeneration by compromising localized 
delivery of kinesin-1 cargoes. 
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Percent (%) Labeled 
Table S2.1: Tau Labeling Efficiencies 
Labeling efficiencies for all Tau constructs used in all in vitro and ex vivo 
experiments. Alexa 488 labeled Tau was used in in vitro and ex vivo dynamics assays. 
Alexa 568 labeled Tau was also used in ex vivo dynamics assays. Alexa 532 labeled 
Tau was used for in vitro binding assays. 
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Table S2.2: Kinesin-1 Behavior in the Presence and Absence of 3RS-Tau Constructs 
Data from in vitro kinesin-1 motility assays. Observed run lengths (Xobserved) and 
microtubule lengths (Lobserved) were used to determine the corrected run length 
(Xcorrected) following previously described methods (Thompson et al., 2013). Median 
p-values for data sets compared to the no Tau condition were calculated using a 
previously detailed resampling method (Thompson et al., 2013). Average velocities 
for kinesin-1 under all conditions tested. There was no change in velocity in the 
presence and absence of Tau. 
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Table S2.3: Behavior of 3RS-Tau Constructs in all Experimental Conditions 
Data from in vitro and ex vivo dynamics assays along with in vitro binding assays. 
Spike Experiments: WT static dwell times were best fit to a two phase exponential 
function which revealed two populations of events with long and short dwell times 
(amplitudes given in table). Y18E static dwell times were best fit to a single 
exponential function one with one average dwell time. Dynamic dwell times were best 
fit to single exponential functions. In vitro binding assays: Affinity (KD) was 
determined by plotting the average intensity Alexa 532 3RS-Tau per unit length of 
microtubule vs Tau concentration. These plots were normalized to max average 
intensity and fit to one site-specific binding with Hill slope curves. Comparable bound 
fraction Experiments: Comparable bound fractions were determined based on in vitro 
binding assays. All static dwell times were best fit to two phase exponential functions 
with both a long and short average dwell time. All dynamic dwell times were best fit 
to single exponential functions. Ex vivo dynamics assays: all dwell times were best fit 
to single exponential functions. 
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Figure S2.1 Cumulative frequency plots of uncorrected kinesin-1 run lengths in 
the presence of unlabeled and Alexa 488 labeled WT 3RS-Tau. 
Average run lengths were calculated through data resampling (10,000 times) as 
previously described (Thompson et al., 2013). 
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Figure S2.2 Cumulative frequency plots for WT and Y18E 3RS-Tau static and 
dynamic dwell times at high concentration. 
 All plots show 95% confidence bands as dotted lines. A) WT 3RS-Tau static dwell 
times were best fit to a two phase exponential function. This revealed an average long 
static dwell time of 15.7 s and a short static dwell time of 1.4 s (R2 = 0.9988; N = 
299). B) Y18E 3RS-Tau static dwell times best fit a one phase exponential function 
and had an average dwell time of 14.5 s (R2 = 0.9960; N = 112). C) Dynamic dwell 
times for WT 3RS-Tau were fit to a one phase exponential function with an average 
dwell time of 1.6 s (R2 = 0.9931; N = 89). D) Y18E 3RS-Tau dynamic dwell times 
were also fit to a one phase exponential function with an average of 1.9 s (R2 = 
0.9883; N = 123). 
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Figure S2.3 Overlay of static and dynamic cumulative frequency plots for WT and 
Y18E 3RS-Tau spike experiments. 
WT 3RS-Tau static events were best fit to a two phase exponential function while Y18E 
3RS-Tau was best fit to a one phase exponential function. Dynamic dwell times for both 
WT and Y18E 3RS-Tau were best fit to one phase exponential functions. Plots show 
95% confidence bands as dotted lines. 
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Figure S2.4 Cumulative frequency plots for WT, Y18A, Y18E and dE 3RS-Tau 
dynamic dwell times.  
All dynamic dwell times were best fit to one phase exponential functions with 95% 
confidence bands as dotted lines. A) WT 3RS-Tau had an average dwell time of 2.8 s 
(R2 = 0.9977). B) Y18A 3RS-Tau had an average dwell time of 1.7 s (R2 = 0.9934). C) 
Y18E 3RS-Tau had an average dwell time of 1.7 s (R2 = 0.9945). D) dE 3RS-Tau had 
and average dwell time of 3.2 s (R2 = 0.9960). There were no notable changes in 
dynamic dwell times for WT and 3RS-Tau constructs. 
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Figure S2.5 Cumulative frequency plots for WT, Y18A, Y18E and dE 3RS-Tau 
static dwell times.  
All static dwell times were best fit to two phase exponential functions with 95% 
confidence bands as dotted lines. A) WT 3RS-Tau had a long dwell time of 13.8 s and 
a short dwell time of 2.1 s (R2 = 0.9991). B) Y18A 3RS-Tau had a long dwell time of 
12.2 s and a short dwell time of 2.2 s (R2 = 0.9985). C) Y18E 3RS-Tau had a long 
dwell time of 9.5 s and a short dwell time of 1.8 s (R2 = 0.9990). D)  dE 3RS-Tau had 
a long dwell time of 14.4 s and a short dwell time of 6.8 s (R2 = 0.9986). There were 
no notable changes in static dwell times (both long and short) for WT and 3RS-Tau 
constructs. 
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Figure S2.6 Cumulative frequency plots for Y18A and Y18E 3RS-Tau ex vivo 
dwell times.  
All dwell times were best fit to single exponential functions with 95% confidence 
bands as dotted lines. A) Y18A 3RS-Tau had a static dwell time of 0.7 s (R2 = 
0.9859), (B) WT 3RS-Tau had a static dwell time of 0.5 s (R2 = 0.9609) and C) Y18E 
3RS-Tau had a static dwell time of 0.8 s (R2 = 0.9966). D) Y18A 3RS-Tau had a 
dynamic dwell time of 0.9 s (R2 = 0.9785), (E) WT 3RS-Tau had a dynamic dwell 
time of 0.4 s (R2 = 0.9578) and (F) Y18E 3RS-Tau had a dynamic dwell time of 1.3 s 
(R2 = 0.9924). Static and dynamic dwell times for Y18A, WT and Y18E 3RS-Tau are 
not appreciably different. However, these dwell times were shorter than those found in 
the in vitro assays due to the increased ionic strength found under physiological 
conditions. 
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Supplemental Movies 
Movie S1 Sample motility assay for kinesin-1 in the presence of labeled WT 3RS-
Tau. TIRF microscopy was used to observe the motility of Q-dot 655 labeled kinesin-1 
on paclitaxel stabilized microtubules coated with Alexa 488 labeled WT 3RS-Tau (200 
nM; 1:5, Tau:tubulin). 500 frames were recorded at 5 fps. Shown here at 15 fps. Arrows 
indicate runs. Data was analyzed using ImageJ as described.  
Movie S2 Sample motility assay for kinesin-1 in the presence of unlabeled Y18E 
3RS-Tau. We observed the motility of Qdot 655 labeled kinesin-1 on rhodamine labeled, 
paclitaxel stabilized microtubules coated with Y18E 3RS-Tau with the same ratio as 
above (Supplemental Movie S1). 500 frames were recorded at 5 fps. Shown here at 5 fps. 
Arrows indicate runs. Data was analyzed using ImageJ as described previously 
(Supplemental Movie S1).  
Movie S3 Sample in vitro dynamics assay. Unlabeled WT 3RS-Tau at 200 nM (1:5; 
Tau:tubulin) spiked with Alexa 488 labeled WT 3RS-Tau (500 pM) behavior on 
rhodamine labeled microtubules. Arrows indicate binding events. 1000 frames were 
recorded at 10 fps shown here at 5 fps. Data was analyzed as described in the Methods 
sections.  
Movie S4 Sample in vitro dynamics assay. Alexa 488 labeled Y18E 3RS-Tau was 
imaged at 1:3000 ratio with rhodamine labeled microtubules. Arrows indicate binding 
events. Data was acquired and analyzed as described in Supplemental Movie S3.  
Movie S5 Sample ex vivo dynamics assay. Squid axoplasm was used to observe the 
behavior of Alexa 488 labeled Y18A 3RS-Tau on Alexa 568 labeled Y18A 3RS-Tau 
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coated microtubules. Images were collected at 3 fps. 100 frames were collected for each 
channel. Upward pointing arrows indicate dynamic events while downward pointing 
arrows indicate static events.  
Movies can be found at http://www.molbiolcell.org. 
 
97 
CHAPTER 3: STRUCTURAL CHANGES UNDERLIE STATIC AND DIFFUSIVE 
TAU BINDING ON THE MICROTUBULE SURFACE 
3.1 Abstract 
The neuronal microtubule associated protein Tau is integral to the regulation of 
axonal transport and has been shown to carry out numerous functions including 
regulation of kinesin-1 cargo delivery. Kinesin-1 cargo transport is regulated through Tau 
participation in signaling cascades and direct modulation of motor movement. Our recent 
observation that N-terminal phosphorylation regulates Tau static-diffusive binding 
equilibrium and ability to modulate kinesin-1 motility, indicates that long range structural 
changes underlie static vs diffusive binding. This observation, coupled with solution and 
microtubule bound studies to determine Tau structure, led us to hypothesize that Tau 
binds the microtubule in multiple conformations. To address the challenge of observing 
structural change for a dynamically bound protein, we used total internal reflection 
fluorescence (TIRF) microscopy and alternating laser excitation (ALEX) to develop a 
three color single-molecule fluorescence resonance energy transfer (smFRET) assay. 
With this assay we have imaged the shortest isoform (3RS) of Tau in both the static and 
diffusive state on the microtubule surface. Using N- and C-termini dual labeled 3RS-Tau, 
we correlate changes in FRET efficiency with behavioral changes to demonstrate the 
efficacy of our approach. Our results show that the N- and C-termini interact while Tau is 
bound statically while this interaction is reduced in the diffusive state. 
3.2 Introduction 
Within the axon the molecular motor based movement of cargo along 
microtubule tracks (fast axonal transport, FAT) is regulated by complex signaling 
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pathways and many microtubule associated proteins (MAPs). The MAP Tau has been 
shown to carry out numerous functions during FAT including regulation of kinesin-1 
based cargo delivery (Kanaan et al., 2012). Tau mutations, aberrant isoform expression, 
and modification all lead to the disruption of FAT and are part of the pathology 
associated with Alzheimer’s disease and other Tauopathies (Martin et al., 2011; Ling, 
2018). Six Tau isoforms are expressed in the adult brain and arise from alternative 
splicing of a single gene (Andreadis, 2005; Ballatore et al., 2007). These isoforms differ 
based on the number of C-terminal microtubule binding repeats (MBRs, 3-4) and N-
terminal acidic inserts (0-2) (Andreadis, 2005; Ballatore et al., 2007). All isoforms have 
an N-terminal phosphatase activating domain (PAD) and proline rich region (PRR) 
(Margeat et al.; Ballatore et al., 2007). All isoforms are subject to post-translational 
modifications including phosphorylation (Lee et al., 2004; Andreadis, 2005; Ballatore et 
al., 2007; Martin et al., 2013b).  
Tau regulates kinesin-1 based cargo transport through participation in signaling 
cascades and direct inhibition of motor motility (McVicker et al., 2011; Kanaan et al., 
2012; Stern et al., 2017). Tau’s direct inhibition of kinesin-1 motility is well documented 
(Vershinin et al., 2007; Dixit et al., 2008; McVicker et al., 2011; Hoeprich et al., 2014). 
We have shown that the level of inhibition is dependent on Tau isoform and microtubule 
lattice structure (McVicker et al., 2011). The shortest isoform, 3RS-Tau is more 
inhibitory to kinesin-1 on paclitaxel stabilized microtubules than the longest isoform 
4RL-Tau (McVicker et al., 2011). These isoform differences extend to Tau’s behavior on 
the microtubule. Tau has been shown to bind the microtubule in a static-diffusive state 
equilibrium (Dixit et al., 2008; Hinrichs et al., 2012; McVicker et al., 2014) which we 
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have demonstrated differs with isoform (McVicker et al., 2014) and correlates with the 
isoform’s ability to inhibit kinesin-1 motility (McVicker et al., 2011; McVicker et al., 
2014). 3RS-Tau which is more inhibitory to kinesin-1 favors static binding on paclitaxel 
microtubules while the less inhibitory isoform 4RL-Tau is shifted towards diffusive 
binding (McVicker et al., 2014). 
The PAD has been shown to facilitate Tau’s interaction with protein 
phosphatase 1 (PP1) which in turn regulates cargo delivery (Kanaan et al., 2012). Fyn 
kinase mediated phosphorylation of tyrosine 18 (Y18), the last amino acid in the PAD, 
prevents the Tau-PP1 interaction (Kanaan et al., 2012). The behavioral and functional 
differences we observed for 4RL- and 3RS-Tau led us to ask whether Tau’s binding 
equilibrium could be regulated by the cell. We observed that phospho-mimetics of Y18 
3RS-Tau induce a shift towards diffusive state binding and reduce both inhibition of 
kinesin-1 and Tau’s affinity for the microtubule surface (Stern et al., 2017). 
Phosphorylation within the MBRs and adjacent regions has been shown to reduce 
microtubule binding affinity (Biernat et al., 1993) but our observation that this occurs 
with phosphorylation in the N-terminal projection region which does not bind the 
microtubule (Goode et al., 2000; Stern et al., 2017), indicates that long range structural 
changes may underlie static vs diffusive binding. Furthermore, phosphorylation mediated 
control of both Tau’s signaling cascade participation and ability to inhibit kinesin-1 
suggests a link between structural and functional regulation.  
Recently, two dynamic folded conformations have been identified for Tau in 
solution (Jeganathan et al., 2006; Elbaum-Garfinkle and Rhoades, 2012). While they 
differ in their finer details, they show that a folded conformation is stabilized by N- and 
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C-termini interactions (Jeganathan et al., 2006; Elbaum-Garfinkle and Rhoades, 2012). 
To date structures underlying static and diffusive microtubule binding have not been 
observed. Initial transmission electron microscopy (TEM) studies of microtubule bound 
Tau showed no distinct bound structure (Cleveland et al., 1977). Hirokawa et al. (1988) 
performed cryo-EM studies of densely packed Tau-microtubule pellets where Tau 
projections from the microtubule surface were clearly visible (Hirokawa et al., 1988), but 
the microtubule bound portion of the protein could not be resolved. More recent cryo-EM 
work with Tau and MAP2c, found that both proteins bind along microtubule 
protofilament ridges (Al-Bassam et al., 2002). Santarella et al. (2004) determined that 
Tau binds to α-tubulin subunits however, their study suggested that Tau binds both along 
and across protofilaments. Though these studies furthered our understanding of the Tau-
microtubule interaction, they also show that Tau decorated microtubules appear to have a 
‘fuzzy’ coat (Al-Bassam et al., 2002; Santarella et al., 2004). This ‘fuzziness’ indicates 
that the portions of Tau that do not interact with the microtubule surface are free to adopt 
multiple conformations (Santarella et al., 2004) that cryo-EM techniques cannot resolve. 
This is further supported by recent nuclear magnetic resonance (NMR) studies which 
suggest that when Tau is bound to the microtubule local folding occurs in MBR inter-
repeat regions (Kadavath et al., 2015). These regions are connected by a flexible linker 
indicating that Tau may have the ability to adopt multiple conformations while bound to 
the microtubule (Kadavath et al., 2015). 
We propose a model of dynamic binding where Tau’s structure while statically 
bound is distinct from its diffusively bound structure. These structural changes create a 
conformational equilibrium underlying a behavioral equilibrium. To address the 
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challenge of observing structural change for a dynamically bound protein, we have 
developed a three color single-molecule fluorescence resonance energy transfer 
(smFRET) (Roy et al., 2008) assay. This assay allows us to image dual labeled Tau 
interacting with labeled microtubules. Using total internal reflection fluorescence (TIRF) 
microscopy and alternating laser excitation (ALEX) (Kapanidis et al., 2005), we have 
imaged both statically and diffusively bound Tau. From these data we can correlate 
changes in FRET efficiency with behavioral changes. Here we demonstrate the efficacy 
of our approach using N- and C-termini dual labeled 3RS-Tau. Our results show that the 
N- and C-termini interact while Tau is bound in the static state and this interaction is 
reduced in the diffusive state. 
3.3 Methods 
All work was done with 1X Brinkley’s Reassembly Buffer 80 (BRB80; 80 mM 
PIPES, 1 mM EGTA, 1 mM MgCl2, pH 6.9 at room temperature) unless otherwise noted 
(Stern et al., 2017).  
Tau Construct Generation Our N&C 3RS-Tau smFRET construct was generated by 
introducing the following changes: T17C, C322I, S346C using the QuikChange II XL 
Site-Directed Mutagenesis Kit (Agilent Technologies, Santa Clara, CA) (Figure 3.1A). 
Similarly, N 3RS-Tau and C 3RS-Tau constructs were generated using the QuikChange 
Mutagenesis Kit to introduce cysteines at T17 and S346 respectively in a C322I construct 
(Figure 3.1A). WT 3RS-Tau and all Tau constructs were expressed in BL21-
CodonPlus(DE3)-RP Escherichia coli cells (Stratagene, La Jolla, CA) and purified using 
Q and SP Sepharose (Sigma-Aldrich, St. Lois, MO) affinity column chromatography as 
previously described (McVicker et al., 2011; McVicker et al., 2014). After purification, 
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samples were dialyzed against 1X BRB80. Protein concentrations were determined using 
the bicinchonic acid (BCA) assay (Pierce, Rockford, IL) and WT 3RS-Tau standards. 
SDS PAGE gels (Bio-Rad, Hercules, CA) were used to validate concentrations.  
Tau Construct Labeling smFRET Construct N&C 3RS-Tau was dual labeled with the 
FRET pair Alexa Fluor® 488/647 (Alexa Fluor® 488 C5 Maleimide and Alexa Fluor
® 647 
C2 Maleimide; Invitrogen Molecular Probes, Carlsbad, CA). N&C 3RS-Tau was 
incubated in 4M guanidine hydrochloride (GndHCl), 1X phosphate-buffered saline (PBS) 
pH 7.4 (diluted from 10X PBS pH 7.4; Gibco® by Life Technologies, Grand Isle, NY) 
and 10 fold molar excess dithiothreitol (DTT) for 10 min at 37 oC. Following this 
incubation, a 2 ml 7K MWCO ZebaTM spin desalting column (Peirce, Rockford, IL) was 
used to remove reducing agents. N&C 3RS-Tau was then incubated with 10 fold molar 
excess of Alexa Fluor® 647 in the presence of 1 mM sodium bicarbonate (to raise the pH 
above 7 and improve labeling) for 24 hr in the dark at room temperature. Two fold molar 
excess Alexa Fluor® 488 was then added for an additional 24 hr incubation. Excess 
fluorophore was removed by three rounds of dialysis against 1X BRB80. The protein 
concentration was determined using both the Modified Lowry Assay (Peirce, Rockford, 
IL) and densitometry performed on SDS PAGE gels. Labeling efficiency was determined 
as described previously (Stern et al., 2017) using the extinction coefficients Alexa Fluor® 
488 – 71,000 cm-1M-1 at 493 nm and Alexa Fluor® 647 – 270,000 cm-1M-1 at 652 nm. 
Labeling efficiency was Alexa 488: 26%, Alexa 647: 79%. 
WT, N and C 3RS-Tau Constructs WT 3RS-Tau and both Tau constructs were singly 
labeled with Alexa Fluor® 647 and 488. For Alexa Fluor® 647 labeling was carried out 
following the method detailed for dual labeling except that there was no 24 hr Alexa 
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Fluor® 488 incubation. For Alexa Fluor® 488, labeling was carried out at as detailed 
previously (McVicker et al., 2014; Stern et al., 2017). Briefly, constructs were incubated 
with 10 fold molar excess DTT for 2 hr at room temperature before the DTT was 
removed with a desalting column. Protein was then incubated with 5 fold molar excess 
fluor at room temperature before excess fluor was removed with a desalting column. 
Protein concentration and labeling efficiency was determined as described previously 
(Stern et al., 2017) using the extinction coefficients listed above. Labeling efficiency was 
Alexa 488 – WT: 42%, N: 50%, C: 75%; Alexa 647 – WT: 60 %, N: 34%, C: 47 %. 
High, Intermediate and Low FRET Oligomer Design The R0 for the FRET pair Alexa 
488/647 was calculated using the equation: 
1: 
 
Where K2 is the orientation factor (assumed to be 2/3) (Shrestha et al., 2015), ϕD is 
quantum yield of donor (0.92) (Johnson, 2010)  and J(𝜆) is the overlap integral of donor 
emission and acceptor excitation spectra defined as:  
2: 
 
Where εA is the acceptor extinction coefficients and FD(𝜆) is the normalized donor 
emission spectrum both measured using a fluorimeter to determine the excitation and 
emission spectra of Alexa 488 and 647 at 200 nM (Supplemental Fig. S2). The R0 was 
determined to be 52.7 Å.  
Based on the R0 DNA oligomers were developed for High, Intermediate and Low FRET 
states. The High FRET control oligomer was designed as follows: 5’-
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/Alexa488/TCCCACCTGTCCATGCCAGCCT/Biotin/-3’ and 5’-
AGGCTGGCATGGACAGGTGGGA/Alexa647/-3’ (Integrated DNA Technologies, 
Coralville, IA) with a FRET pair spacing of 24 Å. The Low FRET control oligomer was 
designed using the same sequence for the High FRET oligomer as follows: 5’-
/Alexa488/TCCCACCTGTCCATGCCAGCCT/Biotin/-3’ and 
5’/Alexa647/AGGCTGGCA TGGACAGGTGGGA-3’ (Integrated DNA Technologies, 
Coralville, IA) with a FRET pair spacing of 73 Å.  The Intermediate FRET control was 
designed with the sequence: 5’/Alexa488/AGGCTGGCATGGACGT/Biotin/-3’ and 5’-
/Alexa647/ACGTCCATG CCAGCCT-3’ (Integrated DNA Technologies, Coralville, IA) 
with a FRET pair spacing of 53 Å. 
Tubulin Purification and Labeling Tubulin was purified as previously described from 
bovine brain obtained from Vermont Livestock & Slaughter (Ferrisburgh, VT) 
(McVicker et al., 2014). For imaging in our three color system, purified tubulin was 
labeled with Alexa Fluor® 405 using methods developed by Hyman et al. (Hyman et al., 
1991). Purified tubulin (20-25 mg) was polymerized at 37 oC for 30 min. Following 
polymerization, microtubules were layered on a warm high cushion buffer (0.1 M 
NaHEPES (pH 8.6) (Sigma-Aldrich, St. Lois, MO), 1 mM MgCl2, 1 mM EGTA, 60% 
(v/v) glycerol) and pelleted at 40,000 rpm, 45 min, 35 oC in an OptimaTM TLX 
Ultracentrifuge (Beckman, Pasadena, CA). The supernatant was aspirated and the 
cushion surface was washed with warm label buffer (0.1 M NaHEPES (pH 8.6), 1 mM 
MgCl2, 1 mM EGTA, 40% (v/v) glycerol). The cushion was then aspirated and the pellet 
resuspended in warm label buffer. The resuspended microtubules were incubated with 10 
fold molar excess Alexa Fluor® 405 for 1 hr at 37 oC with vortexing.  
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To quench labeling, an equal volume of stop buffer (2X BRB80, 100 mM L-
Glutamic acid potassium salt monohydrate (K-glutamate; Sigma-Aldrich, St. Lois, MO), 
40% (v/v) glycerol) was added to the microtubule/dye mixture and incubated for 5 min at 
37 oC. The quenched mixture was placed on a warm low cushion buffer (60% (v/v) 
glycerol, 1X BRB80) and centrifuged at 80,000 rpm, 35 oC for 20 min. The supernatant 
was discarded and warm 1X BRB80 (37 oC) was used to wash the cushion before the 
pellet was resuspended in ice cold 1X depolymerization buffer (50 mM K-glutamate, 5 
mM MgCl2, pH 7.0) and incubated for 30 min at 4 
oC. Depolymerized tubulin was 
centrifuged at 80,000 rpm, 2 oC for 10 min. Supernatant was recovered. 1X BRB80, 4 
mM MgCl2 and 1 mM GTP were added to the supernatant before the mixture was 
incubated on ice for 3 min. This mixture was then incubated at 37 oC for 2 min before ½ 
volume warm glycerol (33% v/v) was added. The solution was incubated for a further 30 
min at 37 oC. Polymerized tubulin was layered onto warm low cushion buffer and 
pelleted at 80,000 rpm, 20 min, 37 oC.  The resulting microtubule pellet was resuspended 
in ice cold 1X BRB80 and incubated at 4 oC for 30 min. Depolymerized tubulin was 
centrifuged a final time at 80,000 rpm, 10 min, 2 oC. Protein concentration was 
determined using Beer-Lambert’s law and the tubulin extinction coefficient of 110,000 
cm-1M-1 at 280 nm. Labeling efficiency was determined in the same manner using the 
Alexa 405 extinction coefficient of 35,000 cm-1M-1 at 401 nm. Tubulin concentration was 
validated using SDS PAGE gels.  
Slide Coating and Chamber Construction Biotin-PEG coating Coverslips (Marienfeld 
High Precision Microscope Cover Glass No. 1.5H (tol. ± 0.5 µm), Azer Scientific, 
Morgantown, PA) were methanol washed and plasma cleaned as previously described 
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(McVicker et al., 2014; Stern et al., 2017). Cleaned slides were then incubated with an 
amino silane mixture (94 % methanol, 5 % acetic acid and 1 % N-(2-aminoethyl)-3-
aminopropyltrimethoxysilane (MilliporeSigma, Billerica, MA)) for 15 min before a 30 
sec sonication and additional 15 min incubation (Joo and Ha, 2012b). Slides were rinsed 
in ddH2O and dried. Following this, slides were incubated with a PEG solution (0.57 mM 
mPEG-Biotin (Laysan Bio Inc, Arab, AL), 22 mM mPEG-SC (Laysan Bio Inc, Arab, 
AL) in 0.1 M NaHCO3 (Sigma-Aldrich, St. Lois, MO) per slide) overnight in a 
humidifying chamber (Joo and Ha, 2012b). Slides were then washed with ddH2O and 
stored at -20 oC until used. Flow chambers were constructed on the day of the experiment 
using double sided tape.  
Silane-PEG coating Glass coverslips were silane-PEG coated as previously described 
(Stern et al., 2017). Briefly, methanol washed slides were plasma cleaned and incubated 
in a silane mixture (97% toluene (Sigma-Aldrich, St. Lois, MO), 2% 2-
methoxy(polyethyleneoxy)propyltrimethoxysilane (Gelest Inc., Morrisville, PA), and 1% 
butylamine (Acros Organics, New Jersey, USA )) with flowing nitrogen gas for 90 min 
(Lowndes and Nelson, 2013). Coverslips were then washed in toluene, dried and cured 
with flowing nitrogen gas for 30 min. Flow chambers were constructed using ARTUS 
shims (ARTUS, Eaglewood, NJ) and Norland optical adhesive (Norland Products, 
Cranbury, NJ) as previously described (Stern et al., 2017). 
Microtubule Polymerization Paclitaxel stabilized Purified, unlabeled tubulin was 
clarified by ultracentrifugation (20 min, 95,000 rpm, 4oC). Clarified tubulin was mixed 
with Alexa Fluor® 405 labeled tubulin at a 1:7 (labeled:unlabeled) ratio and 1 mM GTP 
(Sigma-Aldrich, St. Lois, MO). Microtubules were polymerized for 20 min at 37oC 
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(McVicker et al., 2014; Stern et al., 2017). Following polymerization, microtubules were 
stabilized with 20 µM paclitaxel (paclitaxel; Sigma-Aldrich, St. Lois, MO). Post-
clarification tubulin concentration was calculated using the tubulin extinction coefficient 
of 110,000 cm-1M-1 at 280 nm. 
GMPCPP stabilized Clarified tubulin was mixed with Alexa Fluor® 405 labeled tubulin 
in a 1:7 (labeled:unlabeled) ratio and 20 µM guanosine-5’-[(α,β)-methyleno]triphosphate 
(GMPCPP; Jena Bioscience, Jena, Germany). Microtubules were polymerized by 
incubating small volumes of the mixture stepwise at 37 oC with 20 min incubations 
between additions (McVicker et al., 2014). Post clarification tubulin concentration was 
determined as described above.  
DNA Oligomer Assay 1X BRB80 (pH 7.4 w/KOH) was used to prepare all assay 
buffers. Chambers were washed with 1 mg/mL biotinylated BSA (Sigma-Aldrich, St. 
Lois, MO) for 5 minutes. Chambers were then incubated with one chamber volume 0.2 
mg/mL streptavidin (Sigma-Aldrich, St. Lois, MO) (diluted in 1 mg/mL BSA (Sigma-
Aldrich, St. Lois, MO)) for 5 minutes before one chamber volume of 50 pM desired DNA 
oligomer (diluted in 1 mg/mL biotinylated BSA) was flown in for 5 minutes. Chambers 
were washed with 2X chamber volume 1mg/mL biotinylated BSA to remove non-
adherent oligomers. To prevent drying, chambers were sealed with grease. An inverted 
Eclipse Ti Microscope (Nikon, Melville, NY) with a 100X PlanApo objective lens (1.49 
NA) and auxiliary 1.5X magnification and two iXON Ultra EMCCD cameras (Andor, 
Belfast, N-IRL) running NIS Elements v4.51 (Nikon, Melville, NY) were used to 
perform TIRF microscopy with alternating laser excitation. Alexa 488/647 labeled 
oligomers were imaged by alternating exposure with 640 nm and 488 nm argon lasers 
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and 525/50 and 655 LP emission filters. Three hundred frames were collected at room 
temperature at 0.2 s, 0.11 µm/pixel. 
Behavioral and Intermolecular FRET Assays For both assays, washes and incubations 
were performed with BRB80+OS (BRB80 supplemented with a previously published 
oxygen scavenging system (McVicker et al., 2011)) supplemented with 20 µM paclitaxel 
and 1.5 mM (±)-6-Hydroxy-2,5,7,8-tetramethylchromane-2-carboxylic acid (Trolox) 
(Sigma-Aldrich, St. Lois, MO) (Joo and Ha, 2012a). Silanized flow chambers  were 
incubated with monoclonal anti-β III (neuronal) tubulin antibodies (Sigma-Aldrich, St. 
Lois, MO) at 33 µg/mL for 5 min followed by a 5 min 2X chamber volume wash with 2 
mg/mL BSA (Sigma-Aldrich, St. Lois, MO) (McVicker et al., 2014).  
Behavioral Assay Chambers were incubated for 12 min with paclitaxel stabilized, Alexa 
405 labeled microtubules diluted to 1 – 1.5 µM in 333 – 500 pM N, C or WT 3RS-Tau 
constructs. Finally, chambers were washed with 333 - 500 pM N, C or WT 3RS-Tau for 
2-4 min to remove non-adherent microtubules. All Tau and microtubule dilutions were 
made in warm (37oC) BRB80+OS with paclitaxel and Trolox. Imaging was done using 
the system described for the DNA oligomer assay. Alexa 405 labeled tubulin was excited 
and imaged with a 405 nm argon laser and a 450/50 emission filter. For microtubules, 10 
frames were collected at room temperature at 0.3 s, 0.11 µm/pixel. Tau was imaged using 
the laser and filter combinations described for the DNA oligomers. 300 frames were 
collected at room temperature at 0.2 s, 0.11 µm/pixel.  
Intermolecular smFRET Assay This assay was prepared using the buffers and chamber 
preparation described for the behavioral assay above. Chambers were incubated for 12 
min with paclitaxel stabilized, Alexa 405 labeled microtubules diluted to a final 
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concentration of 1-1.5 uM. An equal mixture of singly labeled (Alexa 488 and 647) N 
and C 3RS-Tau was flown into the chamber at 1 nM (20X the concentration used for 
smFRET experiments) before imaging. Imaging was carried out using the system detailed 
in the DNA oligomer assay and data was collected as for the behavioral assay. 
smFRET Assay For imaging, washes and incubations were performed with BRB80+OS 
(BRB80 supplemented with a previously published oxygen scavenging system 
(McVicker et al., 2011)) supplemented with 1.5 mM (±)-6-Hydroxy-2,5,7,8-
tetramethylchromane-2-carboxylic acid (Trolox) (Sigma-Aldrich, St. Lois, MO) (Joo and 
Ha, 2012a). Silanized flow chambers (McVicker et al., 2014) were incubated with 
monoclonal anti-β III (neuronal) tubulin antibodies (Sigma-Aldrich, St. Lois, MO) at 33 
µg/mL for 5 min followed by a 5 min 2X chamber volume wash with 2 mg/mL BSA 
(Sigma-Aldrich, St. Lois, MO). Chambers were then incubated for 12 min with paclitaxel 
or GMPCPP stabilized, Alexa 405 labeled microtubules diluted to 1.5 µM in 50 pM dual 
labeled N&C 3RS-Tau. Finally, chambers were washed with 50 pM dual labeled N&C 
3RS-Tau for 2-4 min to remove non-adherent microtubules. All Tau and microtubule 
dilutions were made in warm (37oC) BRB80+OS with Trolox. Imaging was done using 
the system described for the DNA oligomer assay. Alexa 405 labeled tubulin was excited 
and imaged with a 405 nm argon laser and a 450/50 emission filter. For microtubules, 10 
frames were collected at room temperature at 0.3 s, 0.11 µm/pixel. Tau was imaged using 
the laser and filter combinations described for the DNA oligomers. 300 frames were 
collected at room temperature at 0.2 s, 0.11 µm/pixel.  
Data Analysis Behavioral Assay Events were tracked using the MTrackJ plugin for FIJI 
if they lasted more than three frames, the signal remained within a snap range of 19 x 19 
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pixels from one frame to the next (snap range chosen based on maximum diffusive range 
of a Tau protein (Konzack et al., 2007)) and the event began and ended on one 
microtubule. Tracks were measured and the points were then exported to Excel. These 
files were analyzed using a custom MATLAB (R2014b) sliding window analysis script 
(Rehan Ali, Unpublished) to calculate mean squared displacement. The mean squared 
displacement was used to separate events as either static or diffusive. Diffusion 
coefficients and alpha values were calculated for diffusive events (Supplemental Table 
S1). 
DNA Oligomers Images were analyzed using FIJI (Schindelin et al., 2012). Dual labeled 
oligomers were identified using kymographs for the donor and acceptor channels 
generated with the Multi Kymograph function. Co-localized events were further 
analyzed. Dual labeled events were tracked using MTrackJ from the ImageScience plugin 
(v3.0.0; Eric Meijering) for FIJI. Tracks were measured in all channels and track points 
were exported to Excel. Points in Excel were further analyzed using MATLAB (R2014b) 
to track the event frame by frame within a 3 x 3 pixel area around the central x,y position 
provided by the track (Rehan Ali, Unpublished). Local background subtraction was 
performed before the average intensity of the event in each frame was calculated. 
Average intensities were used to calculate the constants χ and γ using the following 
equations: 
3: 
 
Where χ is the bleed-through of the donor ( ) into the energy transfer channel ( ) 
was calculated upon acceptor photo-bleaching. 
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4: 
 
Where γ is the sensitivity of the system when detecting the acceptor ( ) versus the 
donor ( ) fluorophore was calculated upon acceptor photo-bleaching. 
Donor/acceptor fluorophore stoichiometry (S) and efficiency of energy transfer (E) for 
each event were calculated as follows: 
5: 
 
6: 
 
Intermolecular FRET Assay Alexa 488 and 647 binding events that overlapped or 
occurred close to each other, were identified by generating kymographs as for oligomer 
analysis. Using the MTrackJ plugin, events were tracked in their respective channels 
(data shown from events tracked in the donor channel). Upon measurement of these 
tracks in each channel, the points were exported to Excel for further analysis with a 
custom MATLAB script as for the behavioral assay. The x,y position associated with 
each track was used to identify the event within the image field for calculation of the 
corrected intensity as described for the DNA oligomer. These corrected intensities were 
then used to calculate average S and E for each event.  
smFRET Assay Dual labeled events were identified as described for oligomer analysis. 
Identified dual labeled events were further analyzed using the MTrackJ plugin. Events 
lasting longer than three frames were tracked using a snap range of 19 x 19 pixels with 
bright centroid tracking. Tracks were measured in each channel and were scored static or 
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diffusive based on their maximum distance to start as described in Stern et al., (2017). 
Points were exported to Excel for further analysis.  
The x, y positions provided by the event points were used to identify events in 
the image field so that the average corrected intensity of the event in each channel from 
frame to frame could be calculated as detailed for oligomer analysis. The average 
corrected intensities for static and diffusive events were then used to calculate average S 
and E for each event using the equations detailed above. 
Statistics Percentages for static and diffusive populations were presented as described for 
the behavioral assay in chapter two. Briefly, the standard deviation shown is the spread in 
the static and diffusive populations for two experiments. 
 Average S and E calculations for high, intermediate and low DNA oligomer 
constructs are based on the averages of 8 events for each oligomer collected over three 
experiments. For intermolecular FRET, average S and E calculations are for averages of 
6 events collected over two experiments. Average S and E calculations for Tau are based 
on averages of 12 events collected over two experiments for both paclitaxel and 
GMPCPP stabilized microtubules. The standard deviation reported for average S and E is 
the deviation for total events. Significance was determined for all S and E calculations 
using a T-test with Welch’s correction assuming different standard deviations for static 
and diffusive events.  
3.4 Results 
Tau’s behavior is not affected by introduction/removal of cysteine residues or labeling in 
the N- and C-termini. To generate our smFRET construct for dual labeling (N&C 3RS-
Tau), we mutated 3RS-Tau’s naturally occurring cysteine to an isoleucine (C322I) and 
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introduced cysteines in the N- and C-termini (T17C and S346C) (Figure 3.1A). In order 
to ensure that these changes did not affect Tau’s behavior while bound to the microtubule 
surface, we generated single cysteine constructs (T17C/C322I and C322I/S346C; Figure 
3.1A). These single cysteine constructs were labeled with either Alexa 488 or 647. Using 
TIRF microscopy, we observed Alexa 488 and 647 labeled WT, N and C 3RS-Tau bound 
to paclitaxel stabilized, Alexa 405 labeled microtubules (Figure 3.1B and 3.2A). 
Behavioral assays performed for donor (Alexa 488) labeled N 3RS-Tau (74 ± 4 % static) 
and C 3RS-Tau (66 ± 5 % static) revealed no significant differences in binding 
equilibrium when compared to WT 3RS-Tau (72 ± 5 % static; P > 0.05) or to each other 
(P > 0.05) (Figure 3.2B and Supplementary Table S3.1). We also observed that labeling 
with acceptor (Alexa 647) did not have a significant effect (P > 0.05) on binding 
equilibrium when comparing N 3RS-Tau (67 ± 5 % static) to C 3RS-Tau (60 ± 5 % 
static) or comparing both to WT 3RS-Tau (65 ± 5 % static; P > 0.05) (Figure 3.2B and 
Supplemental Table S3.1). Dwell times, diffusion coefficients and alpha values 
determined for WT, N, and C 3RS-Tau did not change with fluorophore (Supplementary 
Table S3.1).  
DNA oligomer constructs demonstrate imaging of high, intermediate and low FRET 
states and allow calculation of  γ and χ. Based on the R0 (52.7 Å) calculated for our 
FRET pair (Alexa 488/647), we designed DNA oligomers to measure high (23 Å, E > 
0.9), intermediate (53 Å, E = 0.5) and low (73 Å, E < 0.2) FRET states (Supplemental 
Fig. 3.1). These oligomers were imaged using TIRF microscopy and ALEX to test the 
system’s ability to image both fluorophores in these different FRET states. Upon acceptor 
photo-bleaching (Figure 3.3), χ (donor bleed-through into the acceptor channel) was 
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calculated to be 0.021 while γ (differences in detecting donor and acceptor fluorophores) 
was calculated to be 0.83. These constants were used to correct all S and E calculations. 
For the high FRET oligomer we measured an average S of 0.57 ± 0.09 and an average E 
of 1.1 ± 0.23 (24 Å) (Figure 3.4, Supplementary Fig. 3.1). The intermediate FRET 
oligomer had average S of 0.63 ± 0.13 and an average E of 0.52 ± 0.11 (52 Å) (Figure 
3.4, Supplementary Fig. S3.1). For the low FRET oligomer, we measured an average S of 
0.52 ± 0.09 and an average E of 0.14 ± 0.11 (71 Å) (Figure 3.4, Supplementary Fig. 
S3.1). These results demonstrate that our system is capable of accurately detecting 
changes in fluorophore intensity that correspond to different FRET states. 
Intermolecular FRET does not occur at the smFRET imaging concentration. Though our 
smFRET imaging concentration (50 pM) results in Tau-microtubule ratio of 1:30,000 
(based on a 1.5 µM microtubule imaging concentration), which greatly reduces possible 
Tau-Tau interactions on the microtubule surface, interactions may still occur. Such 
interactions could result in intermolecular FRET leading to false measurements with our 
dual labeled population. To determine if intermolecular FRET occurs, we imaged a 
mixture (1:1:1) of Alexa 488 and Alexa 647 singly labeled WT, N and C 3RS-Tau. Using 
TIRF microscopy and ALEX, we imaged N and C 3RS-Tau at 1 nM (20X smFRET assay 
concentration). Alexa 488 and 647 labeled binding events that overlapped or occurred in 
close proximity (Figure 3.5A) were tracked using MTrackJ. Using MATLAB, intensity 
values associated with these events were used to calculate both S and E. We observed 
that even when binding events overlapped, they had an E of 0.04 ± 0.23 (Figure 3.5B) 
indicating that we were not able to observe intermolecular FRET at 1.5 µM Tau making 
it unlikely that intermolecular FRET is occurring at lower concentrations.  
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3RS-Tau’s N- and C- termini interact in the static state on paclitaxel and GMPCPP 
stabilized microtubules but this interaction is reduced in the diffusive state. Having 
completed our control experiments, we imaged the behavior of dual labeled (Alexa 
488/647) N&C 3RS-Tau on Alexa 405 labeled, paclitaxel stabilized microtubules. Within 
the dual labeled preparation, only ~20 % of the Tau molecules were labeled with both the 
donor and the acceptor. In order to identify dual labeled events for further analysis, we 
imaged using TIRF microscopy with ALEX.  
In addition to separating N&C 3RS-Tau behavior into static and diffusive 
binding events as described in the methods, dual labeled tracks were used to calculate the 
frame by frame intensity values ( , , ) needed to determine average S and E for 
static and diffusive binding events.  
As we have previously shown, 3RS-Tau favors static binding on paclitaxel 
stabilized microtubules (McVicker et al., 2014; Stern et al., 2017). To increase our 
chances to observe diffusive behavior, we imaged N&C 3RS-Tau on GMPCPP 
microtubules (Figure 3.6) where it has been shown that 3RS-Tau’s binding equilibrium is 
shifted towards the diffusive state (McVicker et al., 2014). We found that for both lattice 
structures, the N- and C-termini interact closely in the static state (Figure 3.6&3.7) while 
this interaction is reduced in the diffusive state (Figure 3.6&3.7). 
3.5 Discussion 
Over the last three decades cryo-EM, NMR and single molecule imaging have 
begun to elucidate Tau structure and function on the microtubule surface (Hirokawa et 
al., 1988; Al-Bassam et al., 2002; Santarella et al., 2004; Jeganathan et al., 2006; 
Elbaum-Garfinkle and Rhoades, 2012; Kadavath et al., 2015). Cryo-EM studies hint at 
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the dynamic nature of Tau binding (Al-Bassam et al., 2002). However, the static-
diffusive state binding equilibrium was not observed until recent TIRF studies were 
performed (Hinrichs et al., 2012). If distinct structural changes occur on the microtubule 
surface, they could not be observed with NMR, cyro-EM and solution based FRET 
(Hirokawa et al., 1988; Al-Bassam et al., 2002; Santarella et al., 2004; Jeganathan et al., 
2006; Elbaum-Garfinkle and Rhoades, 2012; Kadavath et al., 2015). In the case of NMR 
and cryo-EM, averages of the microtubule associated portion of the protein were 
observed but no structure could be observed away from the microtubule surface (Al-
Bassam et al., 2002; Santarella et al., 2004; Kadavath et al., 2015). Solution based FRET 
experiments revealed a folded conformation for Tau (Jeganathan et al., 2006; Elbaum-
Garfinkle and Rhoades, 2012) but these assays could not be used to image structural 
differences between static and diffusive binding on the microtubule surface. Though 
these studies did not focus on the structural changes that underlie static versus diffusive 
binding, along with our own observations of Tau N-terminal phosphorylation mediated 
modulation of kinesin-1 motility (Stern et al., 2017), they led us to hypothesize that Tau 
binds the microtubule surface in multiple conformations which are regulated by Tau N- 
and C-termini interactions and that global conformational change underlies static and 
diffusive microtubule binding. In order to observe potential structural changes on the 
microtubule surface, we developed a three color smFRET TIRF assay using ALEX to 
image Alexa 488/647 labeled Tau on Alexa 405 labeled microtubules. 
Based on our hypothesis, any conformational change would be most noticeable 
in the interaction between the N- and C-termini. Therefore we chose N&C 3RS-Tau as a 
first test of our system. Our experimental procedure allows us to correlate behavioral 
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changes with changes in energy transfer efficiency for static and diffusive events. Our 
DNA oligomer controls demonstrate that we are able to measure energy transfer 
efficiencies between 24 Å and 71 Å (Figure 3.3&3.4). Our results report the average 
interactions of N&C 3RS-Tau in the static and diffusive state (Figure 3.6&3.7) however, 
other structural changes exist may occur. 
Our smFRET experiments show that the N- and C-termini interact closely in the 
static state on both paclitaxel and GMPCPP stabilized microtubules while the interaction 
is reduced in the diffusive state (Figure 3.8). This interaction suggests that Tau binds the 
microtubule surface in a folded conformation which is more compact in the static state. 
The more open confirmation that underlies diffusive binding may be the result of Tau 
interactions with tubulin C-terminal tails (CTT). It has previously been shown that 
diffusive behavior is dependent on CTT (Hinrichs et al., 2012). On subtilisin treated 
microtubules the frequency of binding is reduced and those events that do occur are 
predominantly static (Hinrichs et al., 2012). This supports work demonstrating that the 
Tau-microtubule interaction is partially dependent on the CTT and requires interactions 
between the CTT and C-terminal residues of Tau (Al-Bassam et al., 2002; Hinrichs et al., 
2012; Di Maïo et al., 2014). Static binding is then the result of the folded conformation’s 
inability to interact with the CTT due to shielding of the C-terminal region.  
Previous work by our group demonstrates that static Tau is more inhibitory to 
kinesin-1 motility than diffusive Tau (McVicker et al., 2011; Stern et al., 2017). A folded 
conformation preventing Tau C-terminal interactions with the CTT would allow for more 
stable lattice interactions promoting static binding. This would in turn allow Tau to 
modulate kinesin-1 run-length. The phosphorylation mediated shift towards diffusive 
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binding would result from disruption of N- and C-termini interactions leading to an 
equilibrium shift. In addition to regulating kinesin-1 motility, Tau participates in 
signaling cascades governing cargo delivery (Morfini et al., 2002; LaPointe et al., 2009; 
Kanaan et al., 2012). Phosphorylation of Y18 which facilitates a diffusive state shift, has 
also been shown to prevent Tau from participating in signaling cascades (Morfini et al., 
2002; LaPointe et al., 2009; Kanaan et al., 2012). Therefore, the more stable lattice 
interactions found in the static state could facilitate Tau involvement in signaling. 
However, the more open conformation of the diffusive state would be more accessible for 
signaling though this would be phosphorylation dependent. Based on this reasoning Tau 
participation in signaling cascades could occur in either the static or diffusive state but, 
protein-protein interactions might further alter Tau conformation on the microtubule 
surface. Hirokawa et al. (1988) observed an open, extended N-terminal in cryo-EM 
micrographs of densely packed Tau-microtubule pellets. It has been shown that Tau 
bundles microtubules potentially through N-terminal/N-terminal interactions (Chen et al., 
1992; Rosenberg et al., 2008; Choi et al., 2017). This would lead to the extended N-
terminal projections observed by Hirokawa et al. (1988). We do not know how Tau-Tau 
interactions or other binding partners would further affect Tau on the microtubule 
surface. 
Further work must be done with other smFRET constructs to determine the 
overall structure of Tau on both paclitaxel and GMPCPP stabilized microtubules. 
Additionally, Tau is a heavily post translationally modified protein (Martin et al., 2011). 
As we have previously demonstrated, phosphorylation plays a role in regulating Tau’s 
behavior and function on the microtubule surface (Stern et al., 2017). It is not hard to see 
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how disease state modifications to Tau would affect its bound structure and therefore its 
function beginning at early disease development time points. Future work with Tau will 
allow us to understand how disease and non-disease state phosphorylation events (such as 
Y18 phosphorylation) may affect Tau’s bound structure and whether the structural 
changes we have observed in vitro occur in vivo under normal and disease state 
conditions. This work highlights the need for continued study of factors which regulate 
Tau’s static-diffusive microtubule binding equilibrium. 
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Figure 3.1: Tau constructs and imaging setup. 
A) To create the 3RS-Tau constructs used in these experiments, site directed 
mutagenesis was used to change the naturally occurring cysteine to an isoleucine 
(C322I), which is the residue that occurs in other binding repeats at this position. 
Residues in the N- and C- termini (T17 and S346) were mutated to cysteines to create 
N&C 3RS-Tau. B) An inverted Eclipse Ti Microscope with two iXON Ultra EMCCD 
cameras was used to perform TIRF microscopy with ALEX. Labeled Tau was imaged 
by alternating exposure with 640 nm and 488 nm argon lasers. Alexa 405 labeled 
microtubules were imaged with a 405 nm laser.  
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Figure 3.2: Comparison of Singly labeled N 3RS-Tau and C 3RS-Tau to WT 
3RS-Tau. 
To control for the effect of labeling 3RS-Tau at the N- or C-termini with either Alexa 
488 or 647, single cysteine constructs (N 3RS-Tau and C 3RS-Tau) were labeled with 
either Alexa 488 or 647. TIRF microscopy was used to perform behavioral assays 
comparing Alexa 488 or 647 singly labeled WT, N and C 3RS-Tau. A) Kymographs 
of N 3RS-Tau and C 3RS-Tau labeled with either Alexa 488 or 647. All constructs 
demonstrated static (straight lines) and diffusive (jagged lines) binding. B) Histogram 
of percent static binding for WT, N and C 3RS-Tau labeled with Alexa 488 and 647. 
No significant difference was observed for either label or labeling position (p > 0.05). 
See Supplemental Table S2.1. 
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Figure 3.3: Kymographs for DNA oligomer smFRET controls of High, 
Intermediate and Low FRET.  
The High FRET oligomer was designed by labeling the 5’ and 3’ end of a two turn 
oligomer with Alexa 488/647. The Intermediate FRET oligomer was designed by 
labeling both 5’ ends of a one and a half turn oligomer with Alexa 488/647. To create 
the Low FRET oligomer, the same sequence used for the High FRET oligomer was 
dual labeled at the 5’ ends with Alexa 488/647. Donor ( ) and acceptor ( ) labeled 
events were tracked and intensities were measured in donor, acceptor and energy 
transfer ( ) channels. These intensities were background corrected and photo-
bleaching events were used to calculate constants for donor bleed through into the 
acceptor channel (χ) and the difference in the system’s sensitivity to detect donor vs. 
acceptor fluorophores (γ). These constants were then used to calculate both FRET 
efficiency and labeling stoichiometry. 
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Figure 3.4: Stoichiometry (S) versus Average Efficiency (E) plots for DNA 
oligomer smFRET controls for High, Intermediate (Inter) and Low FRET states.  
  Dual labeled DNA oligomers of varying length and fluor position were used to test 
the imaging system’s ability to detect changes in FRET efficiency based on the R0 
(arrow; 52.7Å) for Alexa488/647. We found that we were able to detect efficiency 
changes within the Low to High FRET range of 24 Å to 71 Å. Importantly, we were 
also able to distinguish intermediate FRET efficiencies from high FRET efficiencies 
(Intermediate: 0.52 ± 0.11). Furthermore, the average FRET efficiency for the 
Intermediate oligomer agrees with our calculated R0 (52.7 Å).      
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Figure 3.5: Intermolecular FRET was not observed under our smFRET imaging 
conditions.  
A) To ensure that our smFRET events represent only dual labeled single molecule 
binding events and not intermolecular interactions between interacting molecules, we 
imaged singly labeled Alexa 488 and 647 WT, N and C 3RS-Tau both at 20X the 
concentration (1 nM). Kymographs above are representative of overlapping Alexa 
488 ( ) and 647 ( ). No signal was observed in the energy transfer channel ( ). 
B) Average S and E plot for Alexa 488 and 647 singly labeled static and diffusive 
events that overlap tracked in the donor channel (average S = 0.90 ± 0.10; average E 
= 0.04 ± 0.09; N = 9) and measured with MTrackJ in all channels. No significant 
difference was observed compared to the Low DNA oligomer (P > 0.05; T-test with 
Welch’s correction).  
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Figure 3.6: Kymographs of dual labeled N&C 3RS-Tau.  
Static and diffusive events were tracked and measured in the donor, acceptor 
and energy transfer channels ( , , ). Signal was observed in the  
channel for static events on both paclitaxel and GMPCPP stabilized 
microtubules. No signal was observed in this channel for diffusive events on 
either lattice. 
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Figure 3.7: Average S and E plots for static and diffusive. 
There was a significant difference (P < 0.05, T-test with Welch’s correction) 
between static events (E = 0.57 ± 0.21; S = 0.45 ± 0.12; N= 6) and diffusive 
events (E = 0.07 ± 0.26; S = 0.49 ± 0.10; N= 6) on both lattice structures. 
The N- and C-termini of 3RS-Tau interacts more closely in the static state 
than the diffusive state. This indicates that Tau is more folded on the static 
state than the diffusive state on both paclitaxel and GMPCPP. 
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Figure 3.8: Model of N- and C-termini interactions while Tau (red and gray) is 
bound to the microtubule (green) in both the static and diffusive state. 
Our results show that the N- and C-termini interact closely in the static state while the 
interaction is reduced in the diffusive state. Reduced interaction the diffusive state 
may allow for increased interaction between Tau’s C-terminal residues and tubulin’s 
C-terminal tail (CTT). This interaction has previously been shown to facilitate 
diffusive binding (Hinrichs et al. 2012). In the static state, increased N- and C-termini 
interaction may in turn reduce Tau-CTT interactions. These results represent the first 
in vitro single-molecule structural study of dynamic Tau binding on the microtubule 
surface. 
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Table showing behavioral data for WT, N and C 3RS-Tau labeled Alexa 488 or 647. 
All data was collected on Alexa 405 labeled paclitaxel stabilized microtubules. No 
significant difference was found in behavior for any construct with either label 
(Fisher’s Exact Test; p > 0.05). Data was analyzed using a sliding window analysis to 
determine static or diffusive behavior. No differences were seen in static or diffusive 
dwell times and alpha values calculated for diffusive events from each construct and 
labeling condition did not differ greatly. Label type and position does not affect 3RS-
Tau binding behavior. 
Supplemental Table S3.1: Behavioral Data for Singly Labeled 3RS-Tau 
Control Constructs 
132 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Figure S3.1: Biotinylated DNA oligomers dual labeled with Alexa 488/647. 
 Labels placed at fixed distances were used to control for high, intermediate and low 
FRET conditions based on the calculated R0. Upon acceptor photo-bleaching, these 
oligomers were also used to calculate the constants χ (donor bleed through in the 
acceptor channel) and γ (sensitivity differences when detecting donor vs. acceptor 
fluorophores) needed to calculate E and S: 
and  
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CHAPTER 4: CONCLUSIONS AND FUTURE DIRECTIONS 
Tau performs many functions within axonal transport, which must be carefully 
regulated to ensure neuronal health. This work explores the link between regulation of 
Tau behavior and function while examining the structural changes that underlie this 
regulation. In chapter two we demonstrate that phosphorylation regulates Tau function on 
the microtubule surface, while in chapter three we provide the first evidence for structural 
change underlying static versus diffusive binding.  
Work with tyrosine 18 (Y18) up to this point has focused on its participation in 
signaling cascades (LaPointe et al., 2009; Kanaan et al., 2012) and its potential role in 
stabilizing a dynamic folded conformation of Tau in solution (Jeganathan et al., 2006). 
However, Y18 involvement in the regulation of Tau behavior and function on the 
microtubule surface has not been previously demonstrated. It has just recently been 
shown that Tau is able to bind the microtubule in a static-diffusive state equilibrium 
(Hinrichs et al., 2012; McVicker et al., 2014) and the purpose of this equilibrium has just 
begun to be understood (McVicker et al., 2011; Stern et al., 2017). While we work to 
understand Tau’s dynamic bound equilibrium, other questions remain to be answered. 
Within the field, the study of Tau post-translational modifications (PTMs) mostly 
relates to Tau phosphorylation and the studied phosphorylation is usually disease state 
associated (Martin et al., 2013b). While our work with Y18 phosphorylation in chapter 
two represents the first evidence that non-disease state regulation of Tau modification can 
affect its behavior and function, it also serves to highlight a significant gap in our 
knowledge. As a field we have not focused on non-disease state Tau regulation by 
phosphorylation or other PTMs. Additionally, though we have demonstrated that Tau can 
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bind both statically and diffusively ex vivo, no work has not been done to address the 
cellular relevance of this behavior to motor motility modulation.  
Experiments building on the work presented in chapter two should explore the 
relevance of Tau’s static-diffusive state equilibrium on the movement of kinesin-1 within 
the cell. While we have shown that the Y18 phosphorylation mediated shift towards 
diffusive binding is maintained ex vivo, we have not examined ex vivo or in vivo motor 
motility in the presence of Tau. In vivo work could be done by co-expressing GFP labeled 
kinesin-1 with either WT or Y18E 3RS-Tau in a neuronal cell line such as CAD, which 
does not express Tau (Bisig et al., 2009). Given the increase in ionic strength and 
crowding, it is important to establish that the in vitro effect we observed is maintained 
within the cell.  
In addition to cargo binding and motor motility, Y18 has been implicated in the 
stabilization of a solution based dynamic folded conformation of Tau (Jeganathan et al., 
2006). The possible involvement of Y18 in the regulation of Tau structure led us to the 
question the role of structural change in Tau behavior and function on the microtubule 
surface. Phosphorylation of Tau microtubule binding regions has been shown to reduce 
its affinity for the microtubule surface. However, in chapter two we show that Y18 
phospho-mimetics also exhibit reduced affinity for the microtubule surface. Y18 is found 
in Tau’s projection domain, which does not bind the microtubule (Goode et al., 2000). 
This raises the question of how Y18 phosphorylation in the N-terminal region affects the 
affinity of the protein for the microtubule. One possible explanation for this Y18 
mediated drop in affinity is that Y18 phosphorylation affects long range structural 
changes while Tau is bound to the microtubule.  
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Though Tau structure has been studied both on and off the microtubule, no work 
has been done to understand how Tau’s structure may change with static and diffusive 
binding. Cyro-EM creates snap shots of static binding and cannot be used to study Tau’s 
dynamic binding behavior and the structural changes that may occur. Solution based bulk 
and single molecule FRET studies have been used to study Tau microtubule interactions, 
but like cryo-EM are not currently used to study dynamic behavioral changes on the 
microtubule surface. To address this gap in knowledge, we have used smFRET 
techniques detailed in chapter three to observe differences in Tau N- and C-termini 
interactions. 
Our work on Tau’s microtubule bound structure encompasses the development of 
the reagents, imaging and analysis methods needed to test the hypothesis that Tau binds 
the microtubule in distinct conformations which underlie static and diffusive binding. We 
have demonstrated the efficacy of our system using N&C 3RS-Tau to show that there is a 
difference in the average N- and C-termini interactions between the static and diffusive 
state. However, we have not completed testing other labeling positions within the protein 
(Figure 4.1). Preliminary work with N&3 3RS-Tau suggests that there is little to no 
interaction between the N-terminal and the 3rd microtubule binding repeat in both the 
static and diffusive state (Alisa Cario, personal communication). We have yet to test the 
interactions between the C-terminal and the 3rd microtubule binding repeat. The results 
from these three labeling positions (N&C 3RS-Tau, N&3 3RS-Tau and 3&C 3RS-Tau)  
based on previously published solution based FRET assays (Jeganathan et al., 2006) 
should give us an overall structure for Tau bound in both the static and diffusive state 
(Figure 4.1). To validate our work or in the case that the chosen labeling sites are not 
136 
sufficient, other positions previously used for dual labeling such as sites in the 1st and 2nd 
microtubule binding repeats, acidic inserts and proline rich region can be used 
(Jeganathan et al., 2006; Elbaum-Garfinkle and Rhoades, 2012).  
In chapter three we report the average stoichiometry and efficiency of energy 
transfer for static and diffusive behavior based on averages for individual events. 
Therefore, we report average differences when Tau is bound in the static versus diffusive 
state. Since the focus of this work is on average conformational change during static and 
diffusive binding, it is highly likely that additional structural transitions occur that we 
have not observed. Further analysis of our data would allow us to determine how 
dynamic the interactions in the static and diffusive state are. Probability distribution 
analysis can be used to predict the shape of smFRET histograms for molecules 
interconverting between states (Santoso et al., 2010). Fitting the expected probability 
distributions for different states to histograms of our frame-to-frame E data would allow 
us to determine if Tau has dynamic transitions in the static and diffusive state. Similarly, 
Hidden Markov Modeling can be used to detect transition states that have been obscured 
by the noise in a system (McKinney et al., 2006). Using this approach a transition 
probability matrix and emission probability functions could be used to fit our 
experimental data and determine the points at which transitions were likely (McKinney et 
al., 2006). Fluorescence cross-correlation spectroscopy (FCS) in combination with TIRF-
based single-molecule FRET could be used to obtain information about the time-scale of 
dynamics for specific structural transitions in Tau in the presence of microtubules. 
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Figure 4.1: Tau’s Overall Bound Structure 
Work in chapter three shows that Tau’s N- and C-termini on average, interact more 
closely in the static than the diffusive state (solid double-headed arrow). However, 
work must be done to understand the interactions between the N-terminal and the 
microtubule binding repeats (dashed double-headed arrow), and the C-terminal and the 
microtubule binding repeats (dashed double headed arrow). Dual labeled N&3 and 
3&C 3RS-Tau constructs have been made and work has begun with N&3 3RS-Tau. 
Other labeling sites can be chosen in the 1st and 2nd microtubule binding repeats, acidic 
inserts and proline rich region to further define and validate Tau’s microtubule bound 
structure. 
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Ultimately our work with single molecule fluorescence resonance energy 
transfer (smFRET) will allow us to correlate behavioral changes with FRET efficiency 
changes on the microtubule surface. As we have demonstrated, we have the means to 
perform frame-to-frame background correction and calculate average FRET efficiency 
and average stoichiometry of labeling. However, the methods used to determine static 
versus diffusive binding identify whole events as static or diffusive and do not allow us to 
identify state transitions that may occur during an event. The next step is implementing 
MATLAB code for a sliding window analysis to identify these transitions and calculate 
mean squared displacement and α values for diffusive events. We are currently working 
to complete this next phase of analysis which will allow us to better define the static and 
diffusive states and better correlate FRET efficiency changes with changes in behavior.  
Over the years, cryo-EM studies of microtubule bound Tau have attempted to 
solve Tau structure on the microtubule surface. Together, these studies show that Tau 
binds the microtubule along protofilaments potentially close to α-tubulin (Hirokawa et 
al., 1988; Al-Bassam et al., 2002; Santarella et al., 2004). The most recent cryo-EM 
study has been able to resolve microtubule binding repeats to a much higher resolution 
than any other (Kellogg et al., 2018). This study shows that Tau microtubule binding 
repeats bind in tandem along tubulin dimers (Figure 4.2) (Kellogg et al., 2018). Each 
binding repeat was found to be fully extended across three tubulin monomers (Figure 4.2) 
(Kellogg et al., 2018). These results indicate that while on the microtubule surface, the 
microtubule binding repeats are extended but, as with the other cryo-EM studies, the 
regions of Tau that extended away from the microtubule were not resolved.  
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In conjunction with our work in chapter three, these results lead to the hypothesis 
that Tau’s N- and C-termini interactions in the static state facilitate microtubule binding 
repeat extension while bound to the microtubule surface. Unfortunately, the recent cryo-
EM work (Kellogg et al., 2018) did not resolve portions of Tau that extend away from the 
microtubule surface and cannot be used to observe dynamic structural change. However, 
this work highlights new fluor placement positions for use in our smFRET assay. Our 
current dual labeling sites do not take into account changes in the interactions of the 
microtubule binding repeats. While a distance of 80 Å between repeats (Figure 4.2) is 
outside the R0 measured for Alexa 488/647, placement of probes at the end of one repeat 
and the center of another repeat should allow us to observe any changes that may occur to 
the extension of the repeats in the static and diffusive state. If we could replicate the 
results of the cryo-EM work where the microtubule binding repeats are fully extended 
and therefore should be in a low FRET state, we would not only validate our system but 
demonstrate that it can be used to compliment cryo-EM data. Using both approaches 
would allow us to make significant progress in our understanding of Tau’s dynamic 
structure on the microtubule structure.  
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Figure 4.2: smFRET experiment to determine how microtubule binding repeats 
interact in the static and diffusive state. 
New cryo-EM work shows that Tau microtubule binding repeats (red rectangles) 
interact with the microtubule (green) in tandem. While the dual labeled constructs we 
plan to use for ongoing smFRET assays do not cover interactions between microtubule 
binding repeats, this study highlights the need to include dual label sites within the 
binding repeats. Each repeat stretches 80 Å (Kellogg et al., 2018), a distance which is 
outside the range of the Alexa488/647 FRET pair. However, placement of 
fluorophores (yellow/red oval) at the end of one repeat and the middle of another 
(~40-50 Å distance) would allow for observation of structural changes with static or 
diffusive binding and allow us to validate our smFRET assay. 
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Figure 4.3: Effect of phosphorylation on Tau’s microtubule bound structure. 
In chapter two we demonstrate that phosphorylation at Y18 affects Tau behavior and 
function on the microtubule surface. Our work in chapter three shows that Tau’s N- 
and C-termini interact more closely in the static than the diffusive state. Given that 
phospho-mimetics of Y18 shift Tau’s binding equilibrium towards the diffusive state, 
we hypothesize that Y18 phosphorylation may disrupt N-C termini interactions 
thereby shifting the structural equilibrium to a more open conformation and the 
behavioral equilibrium towards diffusive binding. Currently, no work has been done to 
determine how phosphorylation affects Tau structure on the microtubule surface. 
Therefore to test this hypothesis we have generated Y18E 3RS-Tau smFRET 
constructs for all three positions (N&C, N&3, 3&C) for use in smFRET assays. 
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In chapter two, we demonstrate that phosphorylation regulates behavioral and 
functional change. However, it is not known how non-disease state phosphorylation 
events affect Tau’s bound structure. In light of our work in chapter’s two and three, we 
can hypothesize that Y18 phosphorylation disrupts N-C termini interactions thereby 
shifting the structural equilibrium to a more open conformation and the behavioral 
equilibrium towards diffusive binding. To test this hypothesis, we have generated Y18E 
3RS-Tau smFRET constructs for all three positions (N&C, N&3, 3&C) for use in 
smFRET assays (Figure 4.3). 
In addition to understanding how post-translational modifications affect Tau 
structure, we are also able to ask questions about other aspects of the Tau-microtubule 
interaction including patch formation, interactions with the microtubule in the static and 
diffusive state, and the physiological relevance of Tau structure. It has been shown that 
Tau binds the microtubule cooperatively and forms patches in the static state at high 
concentrations (Dixit et al., 2008; McVicker et al., 2014). However, the structural 
changes that underlie these patches and the Tau-Tau interactions that may occur are not 
well understood. It is hypothesized that N-termini intermolecular interactions, possibly 
through the acidic inserts, allow patch formation since 4RL-Tau (two acidic inserts) 
appears to form larger patches than 3RS-Tau (no acidic inserts) (Dixit et al., 2008). To 
determine the structure of Tau within these patches, smFRET total internal reflection 
fluorescence (TIRF) microscopy experiments with alternating laser excitation (ALEX) 
could be performed on unlabeled microtubules with high concentrations of Alexa 405 
labeled WT Tau (20-50 nM) spiked with a much lower concentration (500 pM) of Alexa 
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488/647 dual labeled Tau. This would allow for patch identification (Alexa 405) and 
imaging of Tau structure (Alexa488/647) within these patches.  
The future integration of TIRF with fluorescence correlative spectroscopy (FCS) 
would allow us to identify potential Tau-Tau interactions within patches. Single donor 
and acceptor N-terminal labeled populations of WT Tau could be spiked into the same 
experimental setup described above. This technique would allow the resolution of Tau 
molecules within a patch and with the smFRET data would help us understand patch 
formation and composition and how that relates to observed Tau interactions within 
patches.  
As explained in chapter three, tubulin C-terminal tails (CTT) have been shown to 
regulate Tau diffusive binding. In their absence, Tau has been shown to bind statically to 
the microtubule surface (Figure 4.4) (Hinrichs et al., 2012). To further demonstrate the 
differences that underlie static versus diffusive binding and elucidate the involvement of 
the CTT in this process, smFRET assays can be performed on microtubules with and 
without CTT (Figure 4.4) (-/+ subtilisin treatment (Hinrichs et al., 2012)). In addition to 
Tau structural changes with and without CTT, experiments can be performed to better 
understand the interactions that occur between Tau and the CTT. To carry out this 
experiment, the CTT would be acceptor labeled while Tau would be singly labeled with a 
donor probe (perhaps starting with the C-terminal since its truncation has been shown to 
reduce diffusive binding). Tubulin CTT could be tagged for labeling using a number of 
methods the most attractive being tubulin tyrosine ligase attachment of an unnatural 
amino acid (3-formyltyrosine) to the α-tubulin CTT and subsequent labeling with Alexa 
647 hydrazide (Banerjee et al., 2010). This would allow labeling of our existing bovine 
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brain tubulin stock with fluorophore without the need to express tubulin fused with a 
bulky protein tag or fluorescent marker. smFRET experiments could be performed using 
TIRF and ALEX. Though the preparation for these experiments would be challenging, 
they would allow us to better understand the interactions that dictate diffusive behavior. 
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  Figure 4.4: Tubulin C-terminal tails (CTT) allow Tau to bind diffusively. 
Tubulin CTT have been shown to facilitate Tau diffusive binding on the microtubule 
surface. Treatment to remove CTTs leads to the loss of diffusive behavior as seen in 
the kymographs (Hinrichs et al., 2012). Our results for N&C 3RS-Tau show that the 
N- and C-termini are farther apart in the diffusive state than the static state. This 
change in interaction may be due to Tau C-terminal interactions with tubulin CTT. 
The Tau C-terminal has been shown to interact with the CTT and truncation of the Tau 
C-terminal leads to loss of diffusive binding (Hinrichs et al., 2012). smFRET assays of 
dual labeled Tau with and without the CTT would allow us to observe how the 
presence of the CTT affects Tau structure. Additionally, smFRET could also be 
performed between the Tau C-terminal and the CTT to increase our understanding of 
the interactions that take place between Tau and tubulin. Figure (kymographs) adapted 
from Hinrichs et al., (2012) in accordance with the Creative Commons Attribution 
license. 
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Our ultimate goal is to adapt this smFRET assay for the identification of small 
molecules or other agents that may be efficacious in stabilizing non-disease state 
conformations under disease state conditions. One of the first steps to determining the 
feasibility of this idea is to establish that the structural changes we observed in vitro 
occur under physiological conditions. Increasing salt concentration and adding crowding 
agents to our existing smFRET assays would allow us to mimic some but not all of the 
conditions present in the cell. Carrying out smFRET experiments in squid axoplasm 
could be a means to recreate physiological conditions before moving to more challenging 
systems such as mammalian neuronal cell types. Squid axoplasm could be prepared as 
detailed in chapter two. Alexa 405 labeled Tau would be used to coat the axoplasmic 
microtubules and low concentrations of dual labeled Tau would be spiked in to observe 
structural changes of Tau on axoplasmic microtubules.  
 After confirming that the changes we observe in vitro occur under physiological 
conditions, we can test our smFRET assay’s ability to detect structural changes in the 
presence of single molecules. Heparin is known to induce a disease state conformation of 
Tau and has been used to study Tau conformational change in solution (Elbaum-
Garfinkle and Rhoades, 2012). We could image dual labeled Tau interacting with Alexa 
405 microtubules in the presence and absence of heparin. This experiment would 
demonstrate our ability to observe structural changes caused an already studied small 
molecule and open the way for us to test other small molecules which may affect Tau 
structure. Comparing Tau structure with and without heparin would also allow us to 
determine which dual labeling position would be best for use in a high throughput screen. 
Ideally, interactions at these positions should only change in the presence of heparin. 
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Using these positions, we could simplify and automate our assay to test small molecule 
libraries for promising targets that restore wildtype interactions to populations of disease 
state Tau. Ultimately, these targets could have use in the treatment of Alzheimers disease 
and other Tauopathies. 
 Though the future experiments discussed above are challenging in their 
execution, they represent ways in which we can build on the work presented here to 
further our understanding of the role of Tau in axonal transport and the means by which it 
regulates motor motility and cargo delivery. The smFRET assay especially, lays the 
groundwork for an entirely new direction of thought and will allow us to answer 
questions, which were previously beyond reach. 
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